15-PGDH Inhibitors and Uses

Heterocyclic compounds are developed to inhibit 15-PGDH, addressing the lack of effective treatments for fibrosis and inflammatory diseases by providing potent inhibitors with therapeutic efficacy and pharmacokinetic advantages.

JP2024542221AActive Publication Date: 2024-11-13WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024529715
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-10
Filing Date
2022-11-18
Publication Date
2024-11-13
Estimated Expiration
2042-11-18

AI Technical Summary

Technical Problem

There are no commercially available drugs with 15-PGDH inhibition pathways to treat diseases such as fibrosis, highlighting the need for new compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase (15-PGDH) activity.

Method used

Development of heterocyclic compounds represented by formula I, their solvates, pharmaceutically acceptable salts, or prodrugs, which act as potent 15-PGDH inhibitors.

Benefits of technology

The compounds effectively inhibit 15-PGDH activity, showing significant inhibitory effects and potential therapeutic benefits in treating fibrotic and inflammatory diseases, including pulmonary fibrosis and liver regeneration, with favorable pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542221000001_ABST
    Figure 2024542221000001_ABST
Patent Text Reader

Abstract

A 15-PGDH inhibitor and its use are disclosed. The 15-PGDH inhibitor is a heterocyclic compound represented by formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of the pharma-ceutically acceptable salt thereof, or a prodrug thereof. The compound has excellent 15-PGDH inhibitory activity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the priority of Chinese patent application No. 202111372073X, filed on November 18, 2021, the priority of Chinese patent application No. 2022108370158, filed on July 15, 2022, and the priority of Chinese patent application No. 2022114082124, filed on November 10, 2022. This application cites the above Chinese patent applications in full.

[0002] The present invention belongs to the medical field, specifically, the present invention relates to 15-PGDH inhibitors and uses. [Background technology]

[0003] The 15-hydroxyprostaglandin dehydrogenase (15-PGDH) gene is located on chromosome 4, 4q34-q35, spreads over about 31 kb, has a total of seven exons, and has a molecular weight of 29 kD. 15-PGDH is composed of 266 amino acids and belongs to the short-chain dehydrogenase (SDR) family. It forms a dimer with two identical subunits, but some claim that it has enzymatic activity only when it exists as a monomer. 15-PGDH is a key enzyme in the degradation and inactivation of prostaglandins (PGs) and related eicosane bioactive substances, and is widely present in normal tissues such as the lungs, kidneys, gastrointestinal tract, thyroid, prostate and placenta of humans and mammals. On the one hand, it can catalyze the oxidation of active 15-hydroxyprostaglandins to 15-ketoprostaglandins with greatly reduced activity, but on the other hand, it can catalyze the oxidation of NAD + In the presence of coenzyme factors, it can degrade some other non-prostaglandin polycyclic aromatic hydrocarbons and reduce the production of carcinogens and tumor-promoting substances under physiological or pathological conditions through oxidation reactions.

[0004] Currently, there are no drugs commercially available that inhibit the 15-PGDH pathway to treat many conditions, including fibrosis, so the development of new compounds that can inhibit the activity of 15-PGDH is of positive significance for the treatment of diseases. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to provide a 15-PGDH inhibitor and its use to overcome the drawback of the lack of a drug with 15-PGDH inhibitory pathway for treating many diseases including fibrosis in the prior art. The compound of the present invention has excellent inhibitory activity against 15-PGDH.

[0006] The present invention solves the above technical problems through the following technical solutions.

[0007] It is an object of the present invention to provide novel compounds for use as 15-PGDH inhibitors.

[0008] In a first aspect of the present invention, there is provided a heterocyclic compound represented by formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of the pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0009] [ka]

[0010] however, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represents a ring atom, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N, NH, O, S, CH2, CH or C; R 1 and R 2are each independently hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl; Or, R 1 and R 2 together with the N atom to which they are linked form a 3- to 11-membered heterocycloalkyl, wherein the 3- to 11-membered heterocycloalkyl further comprises zero, one, or more (e.g., two or three) R 1-1 and when there are a plurality of substituents, the substituents may be the same or different, Each R 1-1 are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxy, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy R is an alkoxycarbonyl C1-C6 alkyl, a C3-C8 cycloalkyl, a C3-C8 cycloalkylcarbonyl, a C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; a and R b are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy or halo C1-C6 alkoxy; m and n are each independently 0, 1, 2, or 3; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a ring atom, X 1 , X 2 , X 3 , X 4 and X 5 are each independently N, O, S, CH2, CH or C; X 4 and X 5 The bond between is a single bond or a double bond, R 3 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarb ... carboxyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; X 4 and X 5 A fragment of a group formed by linking

[0011] [ka]

[0012] In the above, A does not exist or A and X 4 , X 5 the ring atoms together form a 3- to 11-membered heterocycloalkyl, a 5-membered heteroaromatic ring, or a 6-membered heteroaromatic ring, the heteroatoms being independently selected from one or more of N, O, and S; If A does not exist, then X 4 and X 5 are each independently R 4 or R5 is replaced by When A is present, said A may further comprise R 3-1 wherein R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, R 4 and R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl , C1-C6 alkoxycarbonyl, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; R 5 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, optionally one or two R 5-1an aminocarbonyl group substituted with a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; Each of the above R 5-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, C1-C6 alkylsulfonyl group, aminosulfonyl group optionally having one or two C1-C6 alkyl groups, C1-C6 alkylsulfonylamino group, or amino optionally having one or two C1-C6 alkyl groups.

[0013] In a second aspect of the present invention, there is provided a compound represented by formula I', a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0014] [ka]

[0015] In formula I', Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represents a ring atom, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N or C; R 1 and R 2 are each independently hydrogen, C1-C6 alkyl, or C3-C8 cycloalkyl; Or, R 1 and R 2 together with the N atom to which they are linked form a 3-11 membered heterocycloalkyl, wherein the C-C cycloalkyl or 3-11 membered heterocycloalkyl may further comprise R 1-1 is replaced by Each R 1-1 are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino optionally having one or two C1-C6 alkyl groups; R a and R b are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy or halo C1-C6 alkoxy; m and n are each independently 0, 1, 2, or 3; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a ring atom, X 1 , X 2 , X 3 , X 4 and X 5 are each independently N or C; Each R 3 are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy or halo C1-C6 alkoxy; X 4 and X 5 A fragment of a group formed by linking

[0016] [ka]

[0017] In the above, A does not exist or A and X 4 , X 5 the ring atoms together form a 3- to 11-membered heterocycloalkyl, a 5-membered heteroaromatic ring, or a 6-membered heteroaromatic ring, the heteroatoms being selected from one or more of N, O, and S; If A does not exist, then X 4 and X 5 are each independently R 4 or R 5 is replaced by When A is present, said A may further comprise R 3-1 wherein R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, R 4 , R 5 and R 3-1are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy ... and alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups.

[0018] In the present invention, the definitions of certain substituents of the heterocyclic compound represented by formula I are as described below, and the definitions of any substituents not mentioned are as described in any of the schemes above.

[0019] In a preferred embodiment of the present invention, the heteroatom in the 3-11 membered heterocycloalkyl, 5 membered heteroaromatic ring and 6 membered heteroaromatic ring is one or more of N, O or S, the number being 1, 2, 3 or 4.

[0020] In a preferred embodiment of the present invention,

[0021] [ka]

[0022] is phenyl or "a six-membered heteroaromatic ring having one, two or three heteroatoms selected from one or more of N, O and S."

[0023] In a preferred embodiment of the present invention,

[0024] [ka]

[0025] is phenyl or "a six-membered heteroaromatic ring having one, two or three heteroatoms selected from one or more of N, O and S", for example, a pyridine ring.

[0026] In a preferred embodiment of the present invention,

[0027] [ka]

[0028] is "a 6-membered heteroalkyl ring substituted with cyclopropane, the heteroatom number being 1 and the heteroatom being selected from N and O."

[0029] In a preferred embodiment of the present invention,

[0030] [ka]

[0031] means "a 6-membered heteroalkyl ring substituted with cyclopropane having one heteroatom selected from N and O" or "a 6-membered heteroalkyl ring substituted with cyclopropane having one heteroatom selected from N", e.g., a pyridine ring.

[0032] In a preferred embodiment of the present invention,

[0033] [ka]

[0034] It is.

[0035] In a preferred embodiment of the present invention,

[0036] [ka]

[0037] The ring in which is located is connected

[0038] [ka]

[0039] Form.

[0040] In a preferred embodiment of the present invention, the heterocyclic compound of formula I has a structure represented by formula I-1 or I-2.

[0041] [ka]

[0042] In a preferred embodiment of the invention, the solvate is a hydrate.

[0043] In a preferred embodiment of the present invention, the R 1 and R 2 The heterocycloalkyl in the 3- to 11-membered heterocycloalkyl formed together with the N atom linked thereto is a monocyclic heterocycloalkyl, a bridged bicyclic heterocycloalkyl or a spiro bicyclic heterocycloalkyl.

[0044] In a preferred embodiment of the present invention, the R 1 and R 2 The heteroatoms in the 3-11 membered heterocycloalkyl formed together with the N atom linked thereto are one or more of N, O or S, and the number is 1, 2, 3 or 4.

[0045] In a preferred embodiment of the present invention, the R 1 and R 2 The 3- to 11-membered heterocycloalkyl formed together with the N atom linked thereto may further include one or more R 1-1 is replaced by

[0046] In a preferred embodiment of the present invention, the R 1 and R 2 together with the N atom to which they are attached form a 3-8 membered heterocycloalkyl.

[0047] Preferably, the 3- to 8-membered heterocycloalkyl is a monocyclic 3- to 8-membered heterocycloalkyl, a fused bicyclic 3- to 8-membered heterocycloalkyl, or a bicyclic 3- to 8-membered heterocycloalkyl optionally containing a bridged ring or a spiro ring.

[0048] Preferably, the 3-8 membered heterocycloalkyl further comprises 1-3 heteroatoms selected from one or more of N, O and S.

[0049] Preferably, said 3-8 membered heterocycloalkyl is further substituted with halogen or halo C1-C6 alkyl, or said 3-8 membered heterocycloalkyl is further substituted with halogen and / or halo C1-C6 alkyl.

[0050] More preferably, the 3-8 membered heterocycloalkyl is a monocyclic 3-6 membered heterocycloalkyl, a bridged ring bicyclic 6-8 membered heterocycloalkyl or a spiro ring bicyclic 8 membered heterocycloalkyl, the heteroatom being N and / or O, the number being 1 or 2, such as azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolidinyl-fused-cyclopropyl, oxaazaspiro[2.5]octyl, azaspiro[2.5]octyl or octahydrocyclopenta[c]pyrrolidinyl.

[0051] In a preferred embodiment of the present invention, the 3-8 membered heterocycloalkyl is further substituted with C1-C6 alkyl, preferably with 0, 1, 2 or 3 substitutions.

[0052] In a preferred embodiment of the present invention, R 1-1 In the above, the halogen and the halo in the halo C1-C6 alkyl are each independently F, Cl or Br, for example, F.

[0053] In a preferred embodiment of the present invention, R 1-1 Among these, the C1 to C6 alkyl in the C1 to C6 alkyl and the halo C1 to C6 alkyl are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example, methyl.

[0054] In a preferred embodiment of the present invention, R 1-1 wherein the halo C1-C6 alkyl is trifluoromethyl, difluoromethyl or monofluoromethyl (e.g.,

[0055] [ka]

[0056] ).

[0057] In a preferred embodiment of the present invention, R 1 and R 2 together with the N atom to which they are linked form the group:

[0058] [ka]

[0059] In a preferred embodiment of the present invention, R 1 and R 2 together with the N atom to which they are linked form the group:

[0060] [ka]

[0061] In a preferred embodiment of the present invention, R 4 and R 5 In the above, each halogen is independently F, Cl or Br, for example, F.

[0062] In a preferred embodiment of the present invention, R 4 and R 5 Among these, the C1-C6 alkyl in the aminocarbonyl group optionally having one or two C1-C6 alkyl groups is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example, methyl.

[0063] In a preferred embodiment of the present invention, R 4 and R 5 In the above, the aminocarbonyl groups optionally having one or two C1-C6 alkyl groups are each independently

[0064] [ka]

[0065] It is.

[0066] In a preferred embodiment of the present invention, A and X 4 , X 5 The heterocycloalkyl in the 3- to 11-membered heterocycloalkyl group taken together with the ring atoms is a monocyclic cycloalkyl or a spirocyclic bicyclic heterocycloalkyl.

[0067] In a preferred embodiment of the present invention, A and X 4 , X 5The number of heteroatoms in a heterocycloalkyl in a 3- to 11-membered heterocycloalkyl taken together with the ring atoms is 1, 2, 3 or 4.

[0068] In a preferred embodiment of the present invention, A and X 4 , X 5 The 3- to 11-membered heterocycloalkyl that the ring atoms together form is a 3- to 7-membered heterocycloalkyl.

[0069] In a preferred embodiment of the present invention, A and X 4 , X 5 The 3- to 11-membered heterocycloalkyl in which the ring atoms together form a 3- to 11-membered heterocycloalkyl is a monocyclic 3- to 6-membered heterocycloalkyl or a spirocyclic bicyclic 7-membered heterocycloalkyl, the heteroatoms being independently N and / or O and being 1, 2 or 3 in number, e.g., pyrrolidinyl or azaspiro[2.4]heptyl.

[0070] In a preferred embodiment of the present invention, A and X 4 , X 5 The number of heteroatoms in the five-membered or six-membered heteroaromatic ring formed by the ring atoms together is one, two, three or four.

[0071] In a preferred embodiment of the present invention, A and X 4 , X 5 The heteroatoms in the 5- or 6-membered heteroaromatic ring formed together by the ring atoms are N and may number 1, 2 or 3, for example a pyridine ring, a pyrimidine ring or a triazole ring.

[0072] In a preferred embodiment of the present invention, when A is present, it further comprises R 3-1 wherein R 3-1 The number is two.

[0073] In a preferred embodiment of the present invention, R 3-1In the above, the halo in the halo C1-C6 alkyl is F, Cl or Br, for example, F.

[0074] In a preferred embodiment of the present invention, R 3-1 Among these, the C1-C6 alkyl in the C1-C6 alkyl, the halo C1-C6 alkyl and the C1-C6 deuterated alkyl are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example, methyl or ethyl.

[0075] In a preferred embodiment of the present invention, R 3-1 Among these, the haloC1-C6 alkyl is

[0076] [ka]

[0077] It is.

[0078] In a preferred embodiment of the present invention, R 3-1 Among these, the C1 to C6 deuterated alkyl is -CD3.

[0079] In a preferred embodiment of the present invention, R 3-1 Among these, the cycloalkyl in the C3 to C8 cycloalkyl is a monocyclic cycloalkyl.

[0080] In a preferred embodiment of the present invention, R 3-1 Among these, the cycloalkyl in the C3 to C8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0081] In a preferred embodiment of the present invention,

[0082] [ka]

[0083] In a preferred embodiment of the present invention, Z 1 , Z 2 and Z 3 are each independently N, CH or C.

[0084] In a preferred embodiment of the present invention, Z 4 and Z 5 are each independently N, NH, CH2, or CH.

[0085] In a preferred embodiment of the present invention, R 1 and R 2 together with the N atom to which they are linked form a 3- to 11-membered heterocycloalkyl, wherein said 3- to 11-membered heterocycloalkyl further comprises zero, one or more R 1-1 is replaced by

[0086] In a preferred embodiment of the present invention, R 1-1 is halogen, C1-C6 alkyl or haloC1-C6 alkyl.

[0087] In a preferred embodiment of the present invention, the heterocyclic compound of formula I is Z 1 , Z 2 and Z 3 are each independently N or C; Z 4 and Z 5 are each independently N, NH, CH2, or CH; R 1 and R 2 together with the N atom to which they are linked form a 3- to 11-membered heterocycloalkyl, wherein said 3- to 11-membered heterocycloalkyl further comprises zero, one or more R 1-1 is replaced by R 1-1 is halogen, C1-C6 alkyl or haloC1-C6 alkyl, m and n are 0; R 3 is hydrogen, R4 and R 5 are independently halogen, cyano, or an aminocarbonyl group optionally having one or two C1-C6 alkyl groups; R 3-1 are independently oxo (=O), C1-C6 alkyl, haloC1-C6 alkyl, C3-C8 cycloalkyl, or C1-C6 deuterated alkyl; X 4 and X 5 A fragment of a group formed by linking

[0088] [ka]

[0089] The definitions of are as described above.

[0090] Those skilled in the art will recognize that, according to conventions used in the art, in the structural formulae of this application:

[0091] [ka]

[0092] is used to depict a chemical bond, which is understood to be the point at which a moiety or substituent is attached to a core or backbone structure.

[0093] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0094] [ka]

[0095] Where X 4 and X 5 each independently represents a ring atom; X 4 and X 5 are each independently N, CH or C; A and X4 , X 5 together form a 3- to 8-membered heterocycloalkyl, which further comprises R 3-1 wherein R 3-1 The substitution by R may be one or more substitutions, and when there are more than one substituent, the substituents may be the same or different, and each R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl , C1-C6 alkoxycarbonyl, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; Z 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in one aspect of the present invention.

[0096] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0097] [ka]

[0098] Where X 4 and X 5 each independently represents a ring atom; X 4 and X 5 are each independently N or C; A and X 4 , X 5 together form a 3- to 8-membered heterocycloalkyl, which further comprises R 3-1 wherein R 3-1 The substitution by R may be one or more substitutions, and when there are more than one substituent, the substituents may be the same or different, and each R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy ... Z is an alkoxycarbonyl C1-C6 alkyl, a C3-C8 cycloalkyl, a C3-C8 cycloalkylcarbonyl, a C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group or an amino group optionally having one or two C1-C6 alkyl groups; 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in one aspect of the present invention.

[0099] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0100] [ka]

[0101] Here, R 3 , R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxy ... Z is an alkoxycarbonyl C1-C6 alkyl, a C3-C8 cycloalkyl, a C3-C8 cycloalkylcarbonyl, a C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group or an amino group optionally having one or two C1-C6 alkyl groups; 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R a , R b , m and n are as defined in one aspect of the present invention.

[0102] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0103] [ka]

[0104] Here, R 3 is halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, and R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl , C1-C6 alkoxycarbonyl, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; Z 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R a , R b , m and n are as defined in one aspect of the present invention.

[0105] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0106] [ka]

[0107] Here, R 3 is H, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy;

[0108] R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C 1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino optionally having one or two C1-C6 alkyl groups;

[0109] Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R a , R b , m and n are as defined in one aspect of the present invention.

[0110] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0111] [ka]

[0112] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0113] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0114] [ka]

[0115] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0116] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0117] [ka]

[0118] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0119] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0120] [ka]

[0121] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0122] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0123] [ka]

[0124] Here, Z 1 , Z 2 , Z 3 , X1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0125] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0126] [ka]

[0127] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0128] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0129] [ka]

[0130] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b, m and n are as defined in one aspect of the present invention.

[0131] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0132] [ka]

[0133] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0134] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0135] [ka]

[0136] Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in one aspect of the present invention.

[0137] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0138] [ka]

[0139] Here, R 5-1 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarb ... Z is an amino group having optionally one or two C1-C6 alkyl groups, a C3-C8 cycloalkyl group, a C3-C8 cycloalkylcarbonyl group, a C3-C8 cycloalkoxy group, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in one aspect of the present invention.

[0140] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0141] [ka]

[0142] Here, R 5-1is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, a C1-C6 alkylsulfonylamino group or an amino group optionally having one or two C1-C6 alkyl groups; Z 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in one aspect of the present invention.

[0143] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0144] [ka]

[0145] Here, R 5-1is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarb ... Z is an amino group having optionally one or two C1-C6 alkyl groups, a C3-C8 cycloalkyl group, a C3-C8 cycloalkylcarbonyl group, a C3-C8 cycloalkoxy group, an aminocarbonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonyl group, an aminosulfonyl group optionally having one or two C1-C6 alkyl groups, a C1-C6 alkylsulfonylamino group, or an amino group optionally having one or two C1-C6 alkyl groups; 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in the first aspect of the present invention; R 4 does not exist.

[0146] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from the following structures:

[0147] [ka]

[0148] Here, R 5-1is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, C2-C6 alkynyl, halo C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkoxycarbonyl C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkoxy, C1-C6 alkylsulfonyl group, aminosulfonyl group optionally having one or two C1-C6 alkyl groups, C1-C6 alkylsulfonylamino group or amino optionally having one or two C1-C6 alkyl groups; Z 1 , Z 2 , Z 3 , X 1 , X 2 and X 3 is as defined in one aspect of the present invention, and R 1 , R 2 , R 3 , R a , R b , m and n are as defined in the first aspect of the present invention; R 4 does not exist.

[0149] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:

[0150] [ka]

[0151] [ka]

[0152] [ka]

[0153] [ka]

[0154] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:

[0155] [ka]

[0156] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:

[0157] The retention time is 0.743 min under the following SFC conditions.

[0158] [ka]

[0159] Chromatography column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine;

[0160] Isocratic elution: 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine in CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35°C; column pressure: 100 Bar;

[0161] The retention time is 1.670 min under the following SFC conditions.

[0162] [ka]

[0163] Chromatography column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine;

[0164] Isocratic elution: 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine in CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35°C; column pressure: 100 Bar;

[0165] The retention time is 0.816 min under the following SFC conditions.

[0166] [ka]

[0167] Chromatography column: Chiralpak AS-3 50×4.6 mm ID, 3 μm; Mobile phase: Mobile phase A: CO2, Mobile phase B: solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: 40 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine in CO2, flow rate: 3 mL / min; Detector: PDA, column temperature: 35° C.; column pressure: 100 Bar;

[0168] The retention time is 1.477 min under the following SFC conditions.

[0169] [ka]

[0170] Chromatography column: Chiralpak AS-3 50×4.6 mm ID, 3 μm; Mobile phase: Mobile phase A: CO2, Mobile phase B: solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: 40 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine in CO2, flow rate: 3 mL / min; Detector: PDA, column temperature: 35° C.; column pressure: 100 Bar;

[0171] The retention time is 0.764 min under the following SFC conditions.

[0172] [ka]

[0173] Chromatography column: Chiralpak AD-3 50×4.6 mm ID, 3 μm; Mobile phase: Mobile phase A: CO2, Mobile phase B: solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine with CO2, Flow rate: 3 mL / min; Detector: PDA, Column temperature: 35° C.; Column pressure: 100 Bar;

[0174] And the retention time is 1.702 min under the following SFC conditions.

[0175] [ka]

[0176] Chromatography column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; isocratic elution: 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine with CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35° C.; column pressure: 100 Bar.

[0177] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:

[0178] Under the test conditions of Example 1, IC 50 is 12.16nM

[0179] [ka]

[0180] Under the test conditions of Example 1, IC 50 is 3.58nM

[0181] [ka]

[0182] Under the test conditions of Example 1, IC 50 is 1.52nM

[0183] [ka]

[0184] And, under the test conditions of Example 1, IC 50 is 7.42nM

[0185] [ka]

[0186] Under the test conditions of Example 1, IC 50 is 15.8nM

[0187] [ka]

[0188] And, under the test conditions of Example 1, IC 50 is 3.78nM

[0189] [ka]

[0190] In a preferred embodiment of the present invention, the heterocyclic compound represented by formula I is selected from any one of the following compounds:

[0191] Under the test conditions of Example 2, the increase is 0.9.

[0192] [ka]

[0193] Under the test conditions of Example 2, the fold increase is 4.8.

[0194] [ka]

[0195] Under the test conditions of Example 2, the increase is 0.9.

[0196] [ka]

[0197] And, under the test conditions of Example 2, the increase fold is 4.4.

[0198] [ka]

[0199] In a preferred embodiment of the present invention,

[0200] [ka]

[0201] had a total lung fibrosis score of 3.34 under the test conditions of Example 3.

[0202] [ka]

[0203] It is.

[0204] In a preferred embodiment of the present invention,

[0205] [ka]

[0206] is C under the test conditions of Example 5 max is 4480ng / mL

[0207] [ka]

[0208] It is.

[0209] In a preferred embodiment of the present invention,

[0210] [ka]

[0211] is the AUC under the test conditions of Example 5 (0-t)is 33173 h ng / mL

[0212] [ka]

[0213] It is.

[0214] A third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula I as described in the first aspect of the present invention, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof or a prodrug thereof, and a pharma- ceutically acceptable carrier.

[0215] A fourth aspect of the present invention provides the use of a compound of formula I as defined in the first aspect of the present invention, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof or a prodrug thereof, or a pharmaceutical composition as defined in the third aspect of the present invention, including use for inhibiting 15-PGDH and / or for the prevention and / or treatment of a 15-PGDH associated disease and / or as a 15-PGDH inhibitor and / or in the manufacture of a medicament, pharmaceutical composition or formulation for the prevention and / or treatment of a 15-PGDH associated disease.

[0216] Preferably, said 15-PGDH related diseases include, but are not limited to, one, two or more of fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft versus host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, engraftment promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death, blood cell reconstitution, tissue injury, cervical diseases and kidney diseases.

[0217] Preferably, the 15-PGDH-associated disease includes, but is not limited to, one, two or more of fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, promotion of engraftment in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death, blood cell remodeling, tissue damage, cervical disease and kidney disease. Preferably, the 15-PGDH-associated disease includes, but is not limited to, fibrotic diseases (e.g., pulmonary fibrosis, including idiopathic pulmonary fibrosis, hepatic fibrosis, renal fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases [e.g., chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, asthma and exacerbation of lung disease, inflammatory bowel disease (IBD) (e.g., ulcerative colitis and Crohn's disease), peptic ulcers (e.g., NSAID-induced ulcers), autoinflammatory diseases (e.g., Behcet's disease), vasculitis syndromes, acute liver damage, acute kidney injury, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndromes (e.g., chronic prostatitis / chronic pelvic pain syndrome), cardiovascular disease (e.g., pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke, and peripheral circulatory disorders), kidney disease (e.g., chronic kidney disease and renal failure), trauma (e.g., diabetic ulcers, burns, bedsores, shavings, etc.) These include, but are not limited to, one, two or more of acute mucosal injury including Glenn's syndrome, mucosal injury (e.g., mucositis or stomatitis), anti-cancer chemotherapy-related injury (anti-cancer chemotherapy agents are primarily alkylating agents, DNA synthesis inhibitors, DNA gyrase inhibitors) or antimetabolites, cellular or humoral immunotherapy or radiation-related injury), autoimmune disease (e.g., multiple sclerosis or rheumatoid arthritis), graft-versus-host disease (GVHD), hair growth, osteoporosis, ear disease (e.g., hearing loss, tinnitus, dizziness and balance disorders), eye disease (e.g., glaucoma and dry eye), neutropenia, diabetes, underactive bladder, engraftment promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death (e.g., neuropsychiatric disorders, neuropathies, neurotoxicity disorders, neuropathic pain and neurodegenerative disorders), liver regeneration, muscle regeneration (such as muscle atrophy, muscular dystrophy and muscle injury) and cervical disease.

[0218] Preferably, the tissue damage is liver damage and / or muscle damage (eg muscle atrophy and muscular dystrophy).

[0219] Preferably, said 15-PGDH-related disease includes, but is not limited to, idiopathic pulmonary fibrosis (IPF).

[0220] Preferably, the prevention and / or treatment of 15-PGDH-related diseases includes, but is not limited to, liver regeneration.

[0221] Preferably, said 15-PGDH related disease includes, but is not limited to, liver damage.

[0222] Preferably, said 15-PGDH related disease includes, but is not limited to, IBD.

[0223] In a fifth aspect of the present invention, there is provided the use of a compound of formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof or a prodrug thereof, in the manufacture of a medicament for the prophylaxis or treatment of the following diseases; the diseases being one or more of fibrotic diseases, inflammatory diseases or tissue damage.

[0224] The fibrotic disease, the inflammatory disease and the tissue damage are all as described above.

[0225] In a sixth aspect of the present invention, there is provided a method for inhibiting 15-PGDH or preventing and / or treating a 15-PGDH-associated disease, comprising the step of administering to a subject in need thereof a compound represented by formula I as defined in the first aspect of the present invention, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof.

[0226] The 15-PGDH-associated diseases are as described above.

[0227] In a seventh aspect of the present invention, there is provided a method for preventing or treating a disease comprising the step of administering to a subject in need thereof a compound of formula I as defined in the first aspect of the present invention, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof or a prodrug thereof, wherein the disease is one or more of a fibrotic disease, an inflammatory disease or tissue injury.

[0228] The fibrotic disease and the inflammatory disease are both as described above.

[0229] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. [Terms and definitions]

[0230] Unless otherwise specified, the definitions of groups and terms described in the specification and claims of this application, including illustrative definitions, exemplary definitions, preferred definitions, definitions set forth in tables, definitions of specific compounds in the examples, etc., can be combined with each other in any combination, and the group definitions and compound structures after such combinations and combinations should fall within the scope described in the specification of this application.

[0231] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the claimed category belongs. Unless otherwise noted, all patents, patent applications, and publications cited herein are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, the definitions in this section shall prevail.

[0232] It should be understood that the above brief description and the following detailed description are exemplary and explanatory only, and are not intended to limit the scope of the present invention. In this application, the use of the singular includes the plural, unless otherwise specified. Please note that the singular forms used in this specification and claims include the plural of the referent unless the context clearly dictates otherwise. Please also note that the use of "or" means "and / or" unless otherwise specified. Furthermore, the use of the term "comprises" and other forms such as "includes", "includes", "containing" are not limiting.

[0233] For definitions of standard chemical terms, references (such as Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4THED." Vols. A(2000)and B(2001), Plenum Press, New York) may be consulted. Unless otherwise specified, conventional methods within the skill of the art, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy, and pharmacological methods, are used. Unless a specific definition is given, the terms used herein in the relevant descriptions of analytical chemistry, synthetic organic chemistry, pharmaceutical and medicinal chemistry are known in the art. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical manufacture, formulation and delivery, and treatment of patients. For example, reactions and purifications can be carried out using the kit manufacturer's instructions or by methods known in the art or described herein. The techniques and methods described above can generally be carried out according to conventional methods well known in the art, as described in various general and more specific references cited and discussed herein. In this specification, the groups and their substituents may be selected by those skilled in the art to provide stable structural moieties and compounds.

[0234] When a substituent is depicted by a conventional chemical formula written from left to right, the substituent also includes the chemically equivalent substituent that would result if the structural formula were written from right to left. For example, CHO is equivalent to CH. As used herein,

[0235] [ka]

[0236] indicates the site of attachment of the group. As used herein, "R", "R1" and "R 1 " have the same meaning and may be exchanged with each other. Similar definitions have the same meaning for other symbols such as R2.

[0237] The section headings used herein are used for organizational purposes only and should not be construed as limiting the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent applications, articles, books, manuals, and papers, are hereby incorporated by reference in their entirety.

[0238] In addition to the above, as used in the specification and claims of this application, unless specifically stated otherwise, the following terms have the meanings set forth below.

[0239] With respect to the numerical ranges described in the specification and claims of this application, when the numerical range is understood as an "integer", it should be understood as describing the two endpoints of the range and each integer within the range. For example, "integers from 1 to 6" should be understood as describing all integers 0, 1, 2, 3, 4, 5, and 6. When the numerical range is understood as a "number", it should be understood as describing the two endpoints of the range and each integer within the range and all decimal points within the range. For example, "numbers from 1 to 10" should be understood as describing not only all integers 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, but also the sum of at least all integers with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9, respectively, for example, 1 to 3 should be understood as 1, 2, and 3.

[0240] In this application, the term "halogen" alone or as part of another substituent refers to fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

[0241] The term "alkyl" alone or as part of another substituent means a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturated bonds, e.g., 1 to 6 carbon atoms, connected to the remainder of the molecule by a single bond. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, and hexyl. As used herein, the term "alkenyl" means an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon double bonds. As used herein, the term "alkynyl" means an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon triple bonds.

[0242] The term "C1-C6 alkyl" alone or as part of another substituent should be understood to mean a linear or branched, saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or an isomer thereof. In particular, the radical has 1, 2 or 3 carbon atoms ("C1-C3 alkyl"), such as methyl, ethyl, n-propyl or isopropyl.

[0243] The term "cycloalkyl" alone or as part of another substituent refers to a cyclic alkyl. m ~C n "Cycloalkyl" should be understood to represent a saturated carbocyclic ring having m to n atoms. For example, "3- to 15-membered cycloalkyl" or "C3-C 15 "Cycloalkyl" refers to a cyclic alkyl containing 3 to 15, 3 to 9, 3 to 6, or 3 to 5 carbon atoms, which can contain 1 to 4 rings. "3 to 10 membered cycloalkyl" contains 3 to 10 carbon atoms. It includes monocyclic, bicyclic, tricyclic, spirocyclic, or bridged rings. Illustrative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl, or bicyclic hydrocarbon groups such as decalin rings. The term "cycloalkyl" can be used interchangeably with the term "carbocycle".

[0244] The term "heterocycloalkyl," alone or as part of another substituent, refers to a cycloalkyl in which one or more (in some embodiments, 1 to 3) carbon atoms are replaced by a heteroatom, such as, but not limited to, N, O, S, and P. The terms "m- to n-membered heterocycloalkyl" or "C m ~C n"Heterocycloalkyl" should be understood to represent a saturated ring having m to n atoms, where the heterocycloatoms are selected from N, O, S, P, preferably N, O or S. For example, the term "4-8 membered heterocycloalkyl" or "C4-C8 heterocycloalkyl" should be understood to represent a saturated ring having 4 to 8 ring atoms, where 1, 2, 3 or 4 ring atoms are selected from N, O, S, P, preferably N, O or S. "4-10 membered heterocyclyl" means a saturated ring having 4 to 10 ring atoms. When prefixes such as 4-8 membered or 4-10 membered are used to represent heterocycloalkyl, the number of carbons is meant to include the heteroatoms. It includes monocyclic, bicyclic, tricyclic, spiro or bridged rings. Examples of heterocycloalkyl are pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrrolyl, azetidinyl, thiazolidinyl, oxazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazepanyl, oxazepanyl, etc. The term "heterocycloalkyl" can be used interchangeably with the term "heteroalkyl ring."

[0245] The term "alkenyl" alone or as part of another substituent refers to a straight or branched chain monovalent hydrocarbon having 2 to 40 carbon atoms with at least one carbon-carbon sp2 double bond (e.g., C2-C6 alkenyl, also e.g., C2-C4 alkenyl) and includes groups having "cis" and "trans" orientations or "E" and "Z" orientations. Examples of alkenyl include, but are not limited to, vinyl and allyl.

[0246] The term "alkynyl" alone or as part of another substituent refers to a straight or branched chain monovalent hydrocarbon having 2 to 40 carbon atoms with at least one carbon-carbon sp triple bond (e.g., C2-C6 alkynyl, also e.g., C2-C4 alkynyl). Examples of alkynyl include, but are not limited to, ethynyl, propynyl, and the like.

[0247] The term “alkoxy” by itself or as part of another substituent means any of the groups represented by the formula: X refers to the group, where R X is "alkyl" as defined above.

[0248] The term "oxo" alone or as part of another substituent refers to two hydrogens on a methylene being replaced by oxygen; thus, the methylene is replaced by a carbonyl.

[0249] The term "aryl" alone or as part of another substituent refers to a monocyclic or polycyclic carbocyclic ring having 6 to 20 carbon atoms, where at least one is aromatic, where in the ring a ring is non-aromatic, the group may be linked via the aromatic ring or via the non-aromatic ring. Illustrative examples of aryl include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydroindenyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl.

[0250] The term "heteroaromatic ring" alone or as part of another substituent refers to a monocyclic or polycyclic carbocyclic ring in which at least one ring atom is a heteroatom independently selected from oxygen, sulfur and nitrogen, and the remaining ring atoms are C, of ​​which at least one is an aromatic ring. The group may be a carbon or heteroatom group (i.e., may be C-linked or N-linked, where possible), where one ring is a non-aromatic ring, the group may be linked via an aromatic ring or a non-aromatic ring. Illustrative examples of heteroaryl include, but are not limited to, imidazolyl, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furyl, thienyl, benzothienyl, benzofuryl, quinolyl, isoquinolyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, N-methylpyrrolyl, and tetrahydroquinolyl. The term "heteroaromatic ring" can be used interchangeably with the terms "heteroaromatic ring", "heteroaryl", or "heteroaromatic group".

[0251] The term "heteroalkenyl ring" alone or as part of another substituent refers to a monocyclic group having a heteroatom (which monocyclic group has a double bond but is not aromatic), preferably a monocyclic ring of 1, 2 or 3 ring heteroatoms independently selected from N, O and S. Examples of heterocycloalkenyls are: dihydrofuranyl, dihydrothienyl, dihydropyrrolyl, dioxolyl, dihydroimidazolyl, dihydropyrazolyl, dihydrothiazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydrotetrazolyl, tetrahydropyridyl, 3,4-dihydro-2H-pyran, pyranyl, thiopyranyl, dihydropyridyl, dihydropyrazinyl, dihydropyrimidinyl, oxazinyl, dihydrotetrazolyl, and the like. The term "heteroalkenyl ring" can be used interchangeably with the term "heterocycloalkenyl".

[0252] The term "spirocycle" alone or as part of another substituent refers to a polycyclic group that shares one carbon atom (called a spiro atom) between monocyclic rings, which contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. Based on the number of shared spiro atoms between the rings, spirocycloalkyls can be classified as monospirocycloalkyls, bisspirocycloalkyls or polyspirocycloalkyls, with monospirocycloalkyls and bisspirocycloalkyls being preferred. Non-limiting examples of spirocycloalkyls are:

[0253] [ka]

[0254] Includes.

[0255] Also included are spirocycloalkyls where the monospirocycloalkyls and heterocycloalkyls share a spiro atom, non-limiting examples of which are:

[0256] [ka]

[0257] Includes.

[0258] The term "bridged ring" refers to a cyclic hydrocarbon in which any two rings in a compound share two carbon atoms that are not directly bonded, and depending on the number of rings they comprise, they can be divided into bicyclic, tricyclic, tetracyclic, etc. Non-limiting examples are:

[0259] [ka]

[0260] Includes.

[0261] "Haloalkyl" alone or as part of another substituent means branched and straight-chain saturated aliphatic hydrocarbon groups (e.g., ∼CvFw, where v = 1 to 3 and w = 1 to (2v + 1)) containing the specified number of carbon atoms, substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.

[0262] The term "deuterated alkyl," alone or as part of another substituent, refers to an alkyl substituted with one or more deuterium atoms, where alkyl is defined above.

[0263] In this application, "optionally" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes both the occurrence and non-occurrence of the event or circumstance. For example, "optionally substituted aryl" means that the aryl is substituted or unsubstituted, and the description includes both substituted and unsubstituted aryl.

[0264] In this application, the term "salt" or "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. The term "pharmaceutically acceptable salt" refers to those compounds, materials, compositions and / or dosage forms which are within the scope of sound medical judgment, suitable for contact with human and animal tissues, without significant toxicity, irritation, allergic response or other problem or complications, and commensurate with a reasonable benefit / risk ratio.

[0265] "Pharmaceutically acceptable acid addition salt" means a salt formed with an inorganic or organic acid that is capable of retaining the biological effectiveness of the free base without other adverse effects. "Pharmaceutically acceptable base addition salt" means a salt formed with an inorganic or organic base that is capable of retaining the biological effectiveness of the free acid without other adverse effects. In addition to pharmaceutically acceptable salts, other salts are also contemplated by the present invention. These may serve as intermediates in the purification of the compounds or in the preparation of other pharmaceutically acceptable salts, or may be used to identify, characterize, or purify the compounds of the present invention.

[0266] The term "solvate" means that the compound of the present invention or a salt thereof contains a stoichiometric or non-stoichiometric solvent bound by intermolecular non-covalent forces; when the solvent is water, it is a hydrate.

[0267] The term "solvate of a pharma- ceutically acceptable salt" refers to a substance formed after combining a compound with a pharma- ceutically acceptable acid or base and a solvent, including but not limited to water, methanol, ethanol, etc., where the amount of solvent may be stoichiometric or non-stoichiometric. Solvates of pharma- ceutically acceptable salts include, but are not limited to, hydrochloride monohydrates, and the like.

[0268] The term "prodrug" refers to a compound of the present invention that can be converted to a biologically active compound under physiological conditions or by solvolysis. The prodrug of the present invention is produced by modifying a functional group in the compound, and the modification can be removed in a routine operation or in vivo to obtain the parent compound. The prodrug includes a compound formed by binding hydroxyl or amino in the compound of the present invention to any group, and when a prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug separates to form a free hydroxyl or free amino, respectively.

[0269] In this application, "pharmaceutical composition" refers to a formulation of a compound of the present invention with a vehicle generally accepted in the art for delivering a biologically active compound to a mammal (e.g., a human). The vehicle includes a pharmaceutically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration to a living organism and facilitate absorption of the active ingredient, thereby exerting its biological activity.

[0270] In this application, a "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the relevant government regulatory agency as acceptable for human or veterinary use.

[0271] The term "excipient" refers to a medicamentous inactive ingredient. Examples of types of the term "excipient" include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, and diluents. Excipients can improve the handling properties of pharmaceutical formulations, i.e., by increasing flowability and / or adhesion, making the formulation more suitable for direct compression.

[0272] The term "treatment" refers to therapeutic therapy. With respect to a particular disease, treatment refers to (1) alleviating one or more biological manifestations of the disease or condition, (2) interfering with (a) one or more points in the biological cascade leading to or causing the disease or (b) one or more biological manifestations of the disease, (3) ameliorating one or more symptoms, effects, or side effects associated with the disease, or one or more symptoms, effects, or side effects associated with the disease or its treatment, or (4) reducing the disease or one or more biological manifestations of the disease.

[0273] The term "prevention" refers to reducing the risk of acquiring or developing a disease or disorder.

[0274] The term "patient" refers to any animal to which or to which a compound or composition according to an embodiment of the present invention is to be administered, or has been administered, and is preferably a mammal. The term "mammal" includes any mammalian animal, including, but not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, and the like, and is preferably a human.

[0275] The term "therapeutically effective amount" refers to an amount of a compound sufficient to effectively treat a disease or condition described in this application when administered to a patient. The "therapeutically effective amount" varies depending on the compound, the disease and its severity, and the age of the patient being treated, but can be adjusted as needed by one skilled in the art.

[0276] The term "inflammatory bowel disease" refers to IBD and is used to describe diseases involving chronic inflammation of the digestive tract. The main types include ulcerative colitis and Crohn's disease. Ulcerative colitis causes inflammation and ulcers in the surface layers of the large intestine (colon) and rectum. Crohn's disease is characterized by inflammation of the lining of the digestive tract, often affecting the deeper layers of the digestive tract.

[0277] In the reaction of each step, the reaction temperature can be appropriately selected depending on the solvent, starting material, reagents, etc., and the reaction time can also be appropriately selected depending on the reaction temperature, solvent, starting material, reagents, etc. After the reaction of each step is completed, the target compound can be separated and purified from the reaction system according to conventional methods such as filtration, extraction, recrystallization, washing, and silica gel column chromatography. If the target compound does not affect the next reaction, it can be directly transferred to the next reaction without separation and purification.

[0278] Each of the above preferred conditions can be arbitrarily combined to obtain each preferred embodiment of the present invention, without violating the common knowledge in the art.

[0279] Positive progress effect of the present invention: As a result of extensive and thorough research, the present inventor has developed an unexpected heterocyclic compound or its pharma- ceutically acceptable salt, and its preparation method and use. The compound represented by formula I of the present invention has at least one of the following effect advantages:

[0280] (1) The present invention provides a compound represented by formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of the pharma-ceutically acceptable salt thereof, or a prodrug thereof, and the compound represented by formula I has a significant inhibitory effect on 15-PGDH.

[0281] (2) At concentrations between 2.5 nM and 2500 nM, it can significantly increase PGE2 production in a dose-dependent manner, resulting in significant effects on IPF and liver regeneration.

[0282] (3) When combined with the pharmacokinetic data in mice, the compounds of the present invention exhibit excellent pharmacokinetic properties in the body of mice, indicating that they have high safety and good potential for drug development.

[0283] (4) The present invention provides a method and intermediate for preparing a compound represented by formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof, which method has a simple operation, high yield, and high purity, and can be used for industrialized production of pharmaceuticals.

[0284] The above and / or additional aspects and advantages of the present invention will become apparent and will be readily understood from the following detailed description of the embodiments with reference to the accompanying drawings. [Brief description of the drawings]

[0285] [Figure 1] 1 is a graph showing the pulmonary fibrosis scores of animals in each group in the efficacy experiment of an IPF preventive model in Test Example 3 of the present invention, using one-way ANOVA: "***" indicates p<0.001 vs. the sham-operated group (Sham), and "#" indicates p<0.05 vs. the G2 model group. [Diagram 2]1 is a graph showing the pulmonary fibrosis scores of animals in each group in the efficacy experiment of an IPF treatment model in Test Example 4 of the present invention, in which "***" indicates p<0.001 vs. G1-Sham, and T-test: "#" indicates p<0.05 vs. model group, and "##" indicates p<0.01 vs. model group. [Diagram 3] 1 is a graph showing the DAI score of each group in Test Example 7 of the present invention, in which "***" indicates p<0.001 vs. the G2 model control group. [Figure 4] 1 is a graph showing the intestine weight / intestine length / body weight index of each group in Test Example 7 of the present invention, using one-way ANOVA: "***" indicates p<0.001 vs. the G2 model control group. [Diagram 5] 1 is a graph showing the colon damage score of each group in Test Example 7 of the present invention, in which "***" indicates p<0.001 vs. the G2 model control group, and "**" indicates p<0.01 vs. the G2 model control group. [Figure 6] 1 is a graph showing the colon inflammatory cell infiltration score for each group in Test Example 7 of the present invention, in which "***" indicates p<0.001 vs. the G2 model control group, and "*" indicates p<0.05 vs. the G2 model control group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0286] The present invention will be further described below by way of examples, but the present invention is not limited to the scope of the described examples.

[0287] The present invention will be further described below based on specific examples. It should be understood that the following description is only the most preferred embodiment of the present invention and should not be considered as limiting the protection scope of the present invention. Based on a full understanding of the present invention, the experimental methods not shown in the following examples with specific conditions usually follow conventional conditions or follow the conditions recommended by the manufacturer, and those skilled in the art can make modifications that are not essential to the technical solutions of the present invention, and such modifications should be considered to be included in the protection scope of the present invention.

[0288] This application has the following definitions: Symbol or unit: I C 50 : Half-inhibitory concentration, the concentration at which half the maximum inhibitory effect is achieved. M: mol / L. For example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) represents an n-hexane solution of n-butyllithium with a molar concentration of 2.5 mol / L. N: equivalent concentration. For example, 2N hydrochloric acid represents a 2 mol / L hydrochloric acid solution. reagent: NBS: N-bromosuccinimide DMF: N,N-dimethylformamide IPA: Isopropyl alcohol DEA: Diethylamine

[0289] Preparation of Intermediate A1: 6'-Bromo-2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one

[0290] The synthetic route to intermediate A1 is as follows:

[0291] [ka]

[0292] Step 1: Synthesis of 5-bromo-2-methylisoindolin-1-one (A1-2)

[0293] [ka]

[0294] Methyl 4-bromo-2-(bromomethyl)benzoate (1g, 3.26mmol) was added to a mixture of methylamine (1.95ml, 3.9mmol) and triethylamine (0.9ml, 6.52mmol) in 2M tetrahydrofuran in a sealed tube and heated at 100°C for 12h. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with hexane to give 5-bromo-2-methylisoindolin-1-one (500mg, yield: 68%).

[0295] LC-MS, M / Z (ESI): 225.9 [M+H] + .

[0296] Step 2: Synthesis of 6'-bromo-2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (A1)

[0297] [ka]

[0298] 5-Bromo-2-methylisoindolin-1-one (500 mg, 2.21 mmol) was dissolved in DMF (20 ml), 1,2-dibromoethane (499 mg, 2.65 mmol) and cesium carbonate (1.44 g, 4.42 mmol) were added, and the mixture was heated at 100° C. for 12 h. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V)=20:1 to 6:1) to obtain 6'-bromo-2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (250 mg, yield: 44.8%).

[0299] LC-MS, M / Z (ESI): 251.9 [M+H] + .

[0300] Preparation of Intermediate A2: 6'-bromo-2'-(deuteromethyl)-spiro[cyclopropane-1,1'-isoindolin]-3'-one

[0301] [ka]

[0302] The synthesis of intermediate A2 was performed according to the synthesis of intermediate A1, with deuterated methylamine replacing methylamine. LC-MS, M / Z (ESI): 255.1 [M+H] + .

[0303] Preparation of Intermediate A3: 3'-Bromo-6'-methylspiro[cyclopropane-1,5'-pyrrolo[3,4-b]pyridin]-7'(6'H)-one

[0304] The synthetic route to intermediate A3 is as follows:

[0305] [ka]

[0306] Step 1: Synthesis of methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (A3-2)

[0307] [ka]

[0308] 5-Bromo-3-methylpyridine-2-methyl carboxylate (A3-1) (5 g, 21.73 mmol) was dissolved in carbon tetrachloride (50 mL), azobisisobutyronitrile (0.71 g, 4.35 mmol) and NBS (4.64 g, 26.1 mmol) were added, and the mixture was reacted at 80 ° C for 5 h. The mixture was diluted with water (100 mL), extracted with ethyl acetate (100 ml), and the organic phases were combined, washed with saturated saline (100 ml), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified using a silica gel column (petroleum ether: ethyl acetate (V / V) = 5: 1 to 1: 1) to obtain the compound 5-bromo-3-(bromomethyl)pyridine-2-methyl carboxylate (A3-2) (4.5 g, yield: 67%).

[0309] LC-MS, M / Z (ESI): 307.8 [M+H] + .

[0310] Step 2: Synthesis of 3-bromo-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (A3-3)

[0311] [ka]

[0312] Methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (1g, 3.24mmol) was added to a mixture of methylamine (1.95ml, 3.9mmol) and triethylamine (0.9ml, 6.52mmol) in 2M tetrahydrofuran in a sealed tube and heated at 100°C for 12h. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with hexane to give 3-bromo-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (500mg, yield: 68%).

[0313] LC-MS, M / Z (ESI): 226.9 [M+H] + .

[0314] Step 3: Synthesis of 3'-bromo-6'-methylspiro[cyclopropane-1,5'-pyrrolo[3,4-b]pyridin]-7'(6'H)-one (A3)

[0315] [ka]

[0316] 3-Bromo-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (500 mg, 2.20 mmol) was dissolved in DMF (20 ml), 1,2-dibromoethane (496 mg, 2.64 mmol) and cesium carbonate (1.43 g, 4.40 mmol) were added, and the mixture was heated at 100°C for 12 h. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 10:1 to 3:1) to give 3'-bromo-6'-methylspiro[cyclopropane-1,5'-pyrrolo[3,4-b]pyridin]-7'(6'H)-one (250 mg, yield 44.9%).

[0317] LC-MS, M / Z (ESI): 253.0 [M+H] + .

[0318] Example 1: Preparation of 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methylisoindolin-1-one (I-1)

[0319] The synthetic route of the target compound I-1 is as follows:

[0320] [ka]

[0321] Step 1: Synthesis of 6-bromo-1-(4-methoxybenzyl)-1,8-naphthyridin-2(1H)-one (B1-2)

[0322] [ka]

[0323] Dissolve 6-bromo-1,8-naphthyridin-2(1H)-one (500mg, 2.22mmol) in tetrahydrofuran (5ml), add sodium hydrogen (133mg, 3.33mmol, 60% content) under nitrogen gas protection at 0-5℃, react for 1h at 0-5℃ after addition is complete, add 1-(chloromethyl)-4-methoxybenzene (522mg, 3.33mmol) to the reaction system at 0-10℃, react for 5h at 25℃ after addition is complete, and the reaction solution The reaction mixture was quenched with saturated ammonium chloride (50 ml) at 0-10° C. under nitrogen gas protection. After quenching, the mixture was extracted with ethyl acetate (50 ml×2). The organic phases were combined, washed with saturated brine (50 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 6-bromo-1-(4-methoxybenzyl)-1,8-naphthyridin-2(1H)-one (B1-2) (700 mg, yellow crude product), which was used directly in the next step.

[0324] LC-MS, M / Z (ESI): 345.0 [M+H] + .

[0325] Step 2: Synthesis of 6-bromo-3-(4-methoxybenzyl)-1,1a,3,7b-tetrahydro-2H-cyclopropa[c][1,8]naphthyridin-2-one (B1-3)

[0326] [ka]

[0327] Under the protection of nitrogen gas, sodium hydrogen (118 mg, 2.95 mmol, purity: 60%) was dispersed in tetrahydrofuran (5 ml), and trimethylsulfoxonium iodide (574 mg, 2.61 mmol) was added in batches at 0-10°C. After the addition was completed, the mixture was reacted at 0-10°C for 1 h. Under the protection of nitrogen gas, 6-bromo-1-(4-methoxybenzyl)-1,8-naphthyridin-2(1H)-one (600 mg, 1.74 mmol) was added in batches at 25°C. After the addition was completed, the mixture was reacted at 90°C for 2 h. The reaction solution was then washed with saturated ammonium chloride at 0-10°C under the protection of nitrogen gas. The reaction mixture was quenched by adding ammonium hydroxide (30 ml), and then extracted with ethyl acetate (50 ml x 2). The organic phases were combined, washed with saturated saline (50 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 20:1 to 6:1) to obtain the compound 6-bromo-3-(4-methoxybenzyl)-1,1a,3,7b-tetrahydro-2H-cyclopropa[c][1,8]naphthyridin-2-one (B1-3) (yellow solid, 350 mg, yield: 56.1%).

[0328] LC-MS, M / Z (ESI): 359.0 [M+H] + .

[0329] Step 3: Synthesis of 6-bromo-3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine (B1-4)

[0330] [ka]

[0331] Under the protection of nitrogen gas, 6-bromo-3-(4-methoxybenzyl)-1,1a,3,7b-tetrahydro-2H-cyclopropa[c][1,8]naphthyridin-2-one (500 mg, 1.39 mmol) was added to tetrahydrofuran (4 ml), and borane dimethyl sulfide solution (10 M, 1.39 ml, 13.9 mmol) was added dropwise at 0-10°C. After the addition was completed, the reaction was stirred at 60°C for 1 h, and the reaction solution was quenched by adding water (10 ml) under the protection of nitrogen gas at 0-5°C. Then, Extraction with dichloromethane (50ml x 2) was performed, and the organic phases were combined, washed with saturated saline (50ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 200: 1 to 20: 1) to obtain the colorless liquid compound 6-bromo-3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine (B1-4) (400mg, yield: 69.4%).

[0332] LC-MS, M / Z (ESI): 345.0 [M+H] + .

[0333] Step 4: Synthesis of methyl 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate (B1-5)

[0334] [ka]

[0335] At 25°C, under the protection of nitrogen gas, 6-bromo-3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine (400 mg, 1.16 mmol), [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (169 mg, 232 μmol), triethylamine (352 mg, 3.48 mmol) and methanol (10 ml) were added to an autoclave, and the mixture was replaced with nitrogen gas. CO was passed through the reaction mixture, and the mixture was stirred at 120°C and a pressure of 4Mpa for 48 hours. The reaction solution was filtered and concentrated to obtain a crude product, which was then purified by silica gel chromatography (petroleum ether:ethyl acetate (V / V) = 200:1 to 20:1) to obtain a white solid compound 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate methyl (B1-5) (350 mg, yield: 93.1%).

[0336] LC-MS, M / Z (ESI): 325.1 [M+H] + .

[0337] Step 5: Synthesis of 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (B1-6)

[0338] [ka]

[0339] Under the protection of nitrogen gas, 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate methyl ester (340 mg, 1.05 mmol) and lithium hydroxide monohydrate (176 mg, 4.19 mmol) were added to tetrahydrofuran (3 ml) and water (1 ml), and the mixture was reacted at 60°C for 1 h. Water (10 ml) was added to the reaction solution, and the mixture was cooled to 0°C for 1 h. The mixture was adjusted to pH=3-4 with 1M dilute hydrochloric acid at 0°C, extracted with dichloromethane (50ml x 2), and the organic phases were combined, washed with saturated saline (50ml), dried over anhydrous sodium sulfate, filtered, and concentrated to give 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (B1-6) (320mg, yellow solid crude product).

[0340] LC-MS, M / Z (ESI): 310.9 [M+H] + .

[0341] Step 6: Synthesis of (4,4-difluoropiperidin-1-yl)(3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (B1-7)

[0342] [ka]

[0343] Under the protection of nitrogen gas, 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (320 mg, 1.03 mmol), 4,4-difluoropiperidine (249 mg, 2.06 mmol), N,N-diisopropylethylamine (399 mg, 3.09 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (784 mg, 2.06 mmol) were added to N,N-dimethylformamide (4 ml), and the reaction was stirred at 25°C for 16 h after the addition was completed. The reaction solution was reacted, water (30 ml) was added, and then extracted with ethyl acetate (50 ml x 2). The organic phases were combined, washed with saturated saline (50 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 50: 1 to 6: 1) to obtain a white solid compound (4,4-difluoropiperidin-1-yl) (3- (4-methoxybenzyl) -1a, 2, 3, 7b-tetrahydro-1H-cyclopropa [c] [1, 8] naphthyridin-6-yl) methanone (B1-7) (350 mg, 2-step yield: 82.1%).

[0344] LC-MS, M / Z (ESI): 414.3 [M+H] + .

[0345] Step 7: Synthesis of (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (B1-8)

[0346] [ka]

[0347] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (3- (4-methoxybenzyl) -1a, 2, 3, 7b-tetrahydro-1H-cyclopropa [c] [1, 8] naphthyridin-6-yl) methanone (50 mg, 121 μmol) was added to trifluoroacetic acid (0.2 ml), and after the addition was completed, the mixture was stirred at 60 ° C for 4 h to react, and the reaction solution was concentrated under reduced pressure to obtain a yellow solid (B1-8) (35.0 mg), which is the crude product of (4,4-difluoropiperidin-1-yl) (1a, 2, 3, 7b-tetrahydro-1H-cyclopropa [c] [1, 8] naphthyridin-6-yl) methanone.

[0348] LC-MS, M / Z (ESI): 294.2 [M+H] + .

[0349] Step 8: 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methylisoindolin-1-one (I-1)

[0350] [ka]

[0351] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 2-methyl-5-bromoisoindolin-1-one (40.4 mg, 179 μmol), bis(dibenzylideneacetone)palladium (6.86 mg, 11.9 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 23% to 53% B, 9 min) to give the target compound 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methylisoindolin-1-one (I-1) (13.0 mg, yield: 23.5%).

[0352] 1 H NMR (400 MHz, CDCl3) δ 7.98 (d, 1H), 7.80 (d, 1H), 7.65 (d, 1H), 7.26 (s, 1H), 7.25 (s, 1H), 4.34 (d, 2H), 3.84-3.92 (m, 2H), 3.74 (br, 4H), 3.18 (s, 3H), 2.00-2.06 (m, 6H), 1.24-1.26 (m, 1H), 1.07-1.10 (m, 1H).

[0353] LC-MS, M / Z (ESI): 439.3[M+H] + .

[0354] Example 2: Preparation of 3-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (I-2)

[0355] The synthetic route of the target compound I-2 is as follows:

[0356] [ka]

[0357] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (1a,2,3,7b-tetrahydro-1H-cyclopropa [c] [1,8] naphthyridin-6-yl) methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 3-bromo-6-methyl-5,6-dihydro-7H-pyrrolo [3,4-b] pyridin-7-one (40.6 mg, 179 μmol), bis (dibenzylideneacetone) palladium (6.86 mg, 11.9 μmol) and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml) and reacted by stirring at 100 ° C. for 12 h. The reaction solution was concentrated to obtain a crude product. The crude product was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 5:1 to 1:1) to obtain the target compound 3-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (I-2) (15.0 mg, yield: 28.6%).

[0358] 1 H NMR (400 MHz, DMSO) δ 8.60 (d, 1H), 7.93 (d, 1H), 7.84 (d, 1H), 7.80 (d, 1H), 4.45 (s, 2H), 3.87 (s, 2H), 3.60 (br, 4H), 3.10 (s, 3H), 2.18-2.50 (m, 1H), 2.00-2.09 (m, 3H), 1.22-1.23 (m, 2H), 1.06-1.08 (m, 1H), 0.83-0.86 (m, 1H).

[0359] LC-MS, M / Z (ESI): 440.2 [M+H] + .

[0360] Example 3 Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-3)

[0361] The synthetic route of the target compound I-3 is as follows:

[0362] [ka]

[0363] Step 1: 4-Bromo-2-hydrazinopyridine (B3-2)

[0364] [ka]

[0365] 80% hydrazine hydrate solution (17 ml) was added to a solution of 4-bromo-2-fluoropyridine (5 g, 28.4 mmol) in ethanol (50 ml), the reaction mixture was stirred at room temperature for 12 h, concentrated, the residue was diluted with water (50 ml) and extracted with ethyl acetate (50 ml x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered and spin-dried to give 4-bromo-2-hydrazinopyridine (3.7 g, yield: 69.3%).

[0366] LC-MS, M / Z (ESI): 187.9 [M+H] + .

[0367] Step 2: 7-Bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B3-3)

[0368] [ka]

[0369] 4-Bromo-2-hydrazinopyridine (3.2 g, 17.02 mmol) was dissolved in tetrahydrofuran (30 ml), carbonyldiimidazole (5.52 g, 34.0 mmol) was added, and the mixture was stirred at room temperature for 12 h, diluted with water (50 ml), extracted with ethyl acetate (50 ml x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, spin-dried, and slurried with ethyl acetate (10 ml) to give 7-bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (2.2 g, yield: 60.4%).

[0370] LC-MS, M / Z (ESI): 213.9 [M+H] + .

[0371] Step 3: 7-Bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B3-4)

[0372] [ka]

[0373] Iodomethane (995 mg, 7.01 mmol) was added dropwise to a mixture of 7-bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (500 mg, 2.33 mmol) and cesium carbonate (1.14 g, 3.50 mmol) in DMF (5 ml) at room temperature, stirred at room temperature for 3 h, diluted with water (20 ml), extracted with ethyl acetate (20 ml x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 5: 1 to 1: 1) to obtain 7-bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (400 mg, yield: 75%).

[0374] LC-MS, M / Z (ESI): 227.9 [M+H] + .

[0375] Step 4: 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-3)

[0376] [ka]

[0377] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (1a,2,3,7b-tetrahydro-1H-cyclopropa [c] [1,8] naphthyridin-6-yl) methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 7-bromo-2-methyl- [1,2,4] triazolo [4,3-a] pyridin-3 (2H) -one (40.8 mg, 179 μmol), bis (dibenzylideneacetone) palladium (6.86 mg, 11.9 μmol) and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml), and the mixture was reacted at 100 ° C. for 12 h with stirring, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 5:1 to 1:1) to obtain the target compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-3) (20.0 mg, yield: 38.1%).

[0378] The products were resolved by SFC (chromatographic column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: IPA+ACN (0.05 volume percent DEA);

[0379] Isocratic elution: 50% by volume IPA+ACN (0.05% by volume DEA) in CO2, flow rate: 3 mL / min; detector: PDA, column temperature: 35°C; column pressure: 100 Bar). Isomer (I-3A) (RT = 0.743 min) and isomer (I-3B) (RT = 1.670 min) were obtained.

[0380] [ka]

[0381] 1 H NMR (400 MHz, DMSO) δ 8.04 (d, 1H), 7.81 (d, 1H), 7.61 (d, 1H), 6.68 (d, 1H), 6.58 (dd, 2.0 Hz, 1H), 3.90 (d, 1H), 3.70 -3.52 (m, 5H), 3.48 (s, 3H), 2.18 (dt, 1H), 2.13-1.93 (m, 5H), 1.06 (dd, 2H).

[0382] LC-MS, M / Z (ESI): 441.1 [M+H] + .

[0383] Example 4 Preparation of 2-cyclopropyl-7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-4)

[0384] The synthetic route of the target compound I-4 is as follows:

[0385] [ka]

[0386] Step 1: 7-Bromo-2-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B4-1)

[0387] [ka]

[0388] Cyclopropyl bromide (848 mg, 7.01 mmol) was added dropwise to a mixture of 7-bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (500 mg, 2.33 mmol) and cesium carbonate (1.14 g, 3.50 mmol) in DMF (5 ml), stirred at room temperature for 3 h, diluted with water (20 ml), extracted with ethyl acetate (20 ml × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (V / V) = 5: 1 to 1: 1) to obtain 7-bromo-2-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B4-1) (200 mg, yield: 37.5%).

[0389] LC-MS, M / Z (ESI): 253.9 [M+H] + .

[0390] Step 2: 2-Cyclopropyl-7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-4)

[0391] [ka]

[0392] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 7-bromo-2-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (45.5 mg, 179 μmol), bis(dibenzylideneacetone)palladium (6.86 mg, 11.9 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C. for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 5:1 to 1:1) to obtain the target compound 2-cyclopropyl-7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-4) (20.0 mg, yield: 55.7%).

[0393] LC-MS, M / Z (ESI): 467.1 [M+H] + .

[0394] Example 5: Preparation of 6'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (I-5)

[0395] The synthetic route of the target compound I-5 is as follows:

[0396] [ka]

[0397] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (1a,2,3,7b-tetrahydro-1H-cyclopropa [c] [1,8] naphthyridin-6-yl) methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 6'-bromo-2'-methylspiro [cyclopropane-1,1'-isoindoline] -3'-one (45.1 mg, 179 μmol), bis (dibenzylideneacetone) palladium (6.86 mg, 11.9 μmol) and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml) and reacted by stirring at 100 ° C. for 12 h. The reaction solution was concentrated to obtain a crude product. The crude product was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 5:1 to 1:1) to obtain the target compound 6'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2'-methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (I-5) (25.0 mg, yield: 45.1%).

[0398] LC-MS, M / Z (ESI): 465.2 [M+H] + .

[0399] Example 6: Preparation of 6'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2'-(deuterated methyl)spiro[cyclopropane-1,1'-isoindolin]-3'-one (I-6)

[0400] The synthetic route of the target compound I-6 is as follows:

[0401] [ka]

[0402] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl) (1a,2,3,7b-tetrahydro-1H-cyclopropa [c] [1,8] naphthyridin-6-yl) methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 6'-bromo-2'-deuterated methyl spiro [cyclopropane-1,1'-isoindoline] -3'-one (45.7 mg, 179 μmol), bis (dibenzylideneacetone) palladium (6.86 mg, 11.9 μmol) and 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C. for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (V / V) = 5:1 to 1:1) to obtain the target compound 6'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2'-(deuterated methyl)spiro[cyclopropane-1,1'-isoindolin]-3'-one (I-6) (26.0 mg, yield: 46.6%).

[0403] LC-MS, M / Z (ESI): 468.2 [M+H] + .

[0404] Example 7 Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-7)

[0405] The synthetic route of the target compound I-7 is as follows:

[0406] [ka]

[0407] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 7-bromo-2-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one were added. (For the synthesis of B7-1, see WO2020145250A1) (60.6 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 ml), and the mixture was reacted by stirring at 100°C for 12 h. The reaction solution was concentrated to obtain a crude product. The crude product was then purified by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 25% to 56% B, 8 min) to give the target compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-7) (18.8 mg, yield: 21.6%).

[0408] LC-MS, M / Z (ESI): 509.2 [M+H] + .

[0409] Example 8: Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)quinazolin-4(3H)-one (I-8)

[0410] The synthetic route of the target compound I-8 is as follows:

[0411] [ka]

[0412] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 7-bromoquinazolin-4(3H)-one (46.0 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 29% to 60% B, 7 min) to give the target compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)quinazolin-4(3H)-one (I-8) (25.0 mg, yield: 33.0%).

[0413] LC-MS, M / Z (ESI): 438.2 [M+H] + .

[0414] Example 9: Preparation of 4-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-fluoro-N-methylbenzamide (I-9)

[0415] The synthetic route of the target compound I-9 is as follows:

[0416] [ka]

[0417] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 4-bromo-2-fluoro-N-methylbenzamide (47.5 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 20% to 70% B, 9 min) to give the target compound 4-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-fluoro-N-methylbenzamide (I-9) (30.5 mg, yield: 40.3%).

[0418] LC-MS, M / Z (ESI): 445.2 [M+H] + .

[0419] Example 10: Preparation of 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-N-methylpicolinamide (I-10)

[0420] The synthetic route of the target compound I-10 is as follows:

[0421] [ka]

[0422] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 5-bromo-N-methylpicolinamide (44.0 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 18% to 75% B, 10 min) to give the target compound 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-N-methylpicolinamide (I-10) (26.5 mg, yield: 36.4%).

[0423] LC-MS, M / Z (ESI): 428.2 [M+H] + .

[0424] Example 11: Preparation of 4-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)benzonitrile (I-11)

[0425] The synthetic route to the target compound I-11 is as follows:

[0426] [ka]

[0427] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 4-bromo-benzonitrile (37.2 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 ml), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 30% to 80% B, 12 min) to give the target compound 4-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)benzonitrile (28.8 mg, yield: 42.8%).

[0428] 1 H NMR (400 MHz, CDCl3) δ 8.01 (d, 1H), 7.68 (d, 1H), 7.61 (s, 1H), 7.59 (s, 1H), 7.29 (s, 1H), 7.26 (s, 1H), 3.94 (d, 1H), 3.85-3.63 (m, 5H), 2.04 (ddd, 6H), 1.18 (q, 1H), 1.11 (td, 1H).

[0429] LC-MS, M / Z (ESI): 395.2 [M+H] + .

[0430] Example 12: Preparation of 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methylisoquinolin-1(2H)-one (I-12)

[0431] The synthetic route to the target compound I-12 is as follows:

[0432] [ka]

[0433] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (50.0 mg, 170 μmol), cesium carbonate (166 mg, 510 μmol), 6-bromo-2-methylisoquinolin-1(2H)-one (48.7 mg, 205 μmol), bis(dibenzylideneacetone)palladium (9.8 mg, 1.70 μmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98.6 mg, 1.70 μmol) were added to dioxane (1 mL), and the mixture was stirred at 100 ° C for 12 h to react, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated by preparative high-performance liquid chromatography (column: Phenomenex Synergi C 18 150×25 mm×5 μm; solvent: A=water+0.1 volume percent trifluoroformic acid (99%), B=acetonitrile; gradient: 30% to 70% B, 10 min) to give the target compound 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methylisoquinolin-1(2H)-one (I-12) (21.1 mg, yield: 27.5%).

[0434] The resulting products were resolved by SFC (chromatographic column: Chiralpak AS-3 50×4.6 mm ID, 3 μm; mobile phase: mobile phase A: CO2, mobile phase B: IPA+ACN (0.05% by volume of DEA); isocratic elution: 40% by volume of IPA (0.05% by volume of DEA) in CO2; flow rate: 3 mL / min; detector: PDA, column temperature: 35° C.; column pressure: 100 Bar). Isomer I-12A (RT=0.816 min) and isomer I-12B (RT=1.477 min) were obtained.

[0435] [ka]

[0436] 1 H NMR (400 MHz,CDCl3) δ 8.33 (d, 1H), 8.00 (s, 1H), 7.66 (s, 1H), 7.35 (d, 1H), 7.20 (s, 1H), 7.03 (d, 1H), 6.40 (d, 1H), 3.91 (dd, 2H), 3.81-3.62 (m, 4H), 3.58 (s, 3H), 2.09-1.95 (m, 6H), 1.25 (s, 1H), 1.09 (s, 1H).

[0437] LC-MS, M / Z (ESI): 451.2 [M+H] + .

[0438] Example 13: Preparation of 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]quinolin-3-yl)-2-methylphthalazin-1(2H)-one (I-13)

[0439] The synthetic route to the target compound I-13 is as follows:

[0440] [ka]

[0441] The synthesis of compound I-13 was based on compound I-1, and A1-2 was replaced with intermediate B13-1. The synthesis of intermediate B13-1 was based on patent WO2021016333.

[0442] 1 H NMR (400 MHz, CDCl3) δ 8.33 (d, 1H), 8.00 (s, 1H), 7.66 (s, 1H), 7.35 (d, 1H), 7.20 (s, 1H), 7.03 (d, 1H), 6.40 (d, 1H), 3.91 (dd, 2H), 3.81-3.62 (m, 4H), 3.58 (s, 3H), 2.09-1.95 (m, 6H), 1.25 (s, 1H), 1.09 (s, 1H).

[0443] LC-MS, M / Z (ESI): 451.2[M+H] + .

[0444] Example 14: Preparation of 3-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]quinolin-3-yl)-7-methylpyrido[2,3-d]pyridazin-8(7H)-one (I-14)

[0445] The synthetic route to the target compound I-14 is as follows:

[0446] [ka]

[0447] The synthesis of compound I-14 was based on compound I-1, and A1-2 was replaced with intermediate B14-1. The synthesis of intermediate B14-1 was based on patent WO2021016333.

[0448] 1H NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 8.08 (s, 1H), 7.98 (s, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 3.75-4.04 (m, 9H), 2.03-2.13 (m, 5H), 1.18-1.25 (m, 3H).

[0449] LC-MS, M / Z (ESI): 452.2[M+H] + .

[0450] Example 15: Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]quinolin-3-yl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one (I-15)

[0451] The synthetic route to the target compound I-15 is as follows:

[0452] [ka]

[0453] The synthesis of compound I-15 was based on compound I-1, and A1-2 was replaced with intermediate B15-1. The synthesis of intermediate B15-1 was based on patent WO2021016333.

[0454] 1 H NMR (400 MHz, CDCl3) δ 8.89 (d, 1H), 8.08 (s, 1H), 7.99 (d, 1H), 7.73 (d, 1H), 7.61 (d, 1H), 4.02 (d, 1H), 3.66-3.85 (m, 8H), 2.03-2.13 (m, 5H), 1.25-1.31 (m, 3H).

[0455] LC-MS, M / Z (ESI): 452.2[M+H] + .

[0456] Example 16: Preparation of (3-([1,2,4]triazolo[1,5-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)(4,4-difluoropiperidin-1-yl)methanone (I-16)

[0457] The synthetic route to the target compound I-16 is as follows:

[0458] [ka]

[0459] The synthesis of compound I-16 was based on compound I-1, with intermediate B16-1 replacing A1-2.

[0460] 1 H NMR (400 MHz, CDCl3) δ 8.37 (d, 1H), 8.24 (s, 1H), 8.05 (d, 1H), 7.72 (d, 1H), 7.28 (d, 1H), 7.07 (dd, 1H), 4.03 (d, 1H), 3.82 (d, 2H), 3.75 (s, 3H), 2.10 (dd, 2H), 2.02 (s, 4H), 1.22 (dd, 1H), 1.15 (td, 1H).

[0461] LC-MS, M / Z (ESI): 411.2[M+H] + .

[0462] Example 17: Preparation of (3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)(4,4-difluoropiperidin-1-yl)methanone (I-17)

[0463] The synthetic route to the target compound I-17 is as follows:

[0464] [ka]

[0465] The synthesis of compound I-17 was based on compound I-1, with intermediate B17-1 replacing A1-2.

[0466] 1 H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.05 (d, 1H), 7.91 (d, 1H), 7.70 (d, 1H), 7.24 (s, 1H), 6.94 (d, 1H), 4.03 (d, 1H), 3.81 (d, 2H), 3.75 (s, 3H), 2.11 (dd, 2H), 2.02 (s, 4H), 1.18 (ddd, 2H).

[0467] LC-MS, M / Z (ESI): 411.2[M+H] + .

[0468] Example 18: Preparation of 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one (I-18)

[0469] The synthetic route to the target compound I-18 is as follows:

[0470] [ka]

[0471] Step 1: Synthesis of 6-chloro-4-formylnicotinic acid (B18-2)

[0472] [ka]

[0473] n-Butyllithium (40.6 ml, 102 mmol) was added dropwise to a tetrahydrofuran solution (50 ml) of 2,2,6,6-tetramethylpiperidine at -78°C, and after completion of the addition, stirring was continued at -78°C for 30 min, and further stirring was continued at -50°C for 30 min. Then, a tetrahydrofuran solution (25 ml) of 6-chloronicotinic acid (4 g, 25.4 mmol) was added dropwise at -78°C, and after completion of the addition, stirring was continued at -78°C for 30 min, and further stirring was continued at -50°C for 30 min. Then, N,N-dimethylformamide (12 ml, 155.2 mmol) was added dropwise at -78°C, and the mixture was slowly warmed to room temperature and stirred overnight. The reaction system was quenched by adding 2N HCl at 0°C, the pH was adjusted to 7, and most of the tetrahydrofuran solvent was removed by distillation under reduced pressure. The pH was then adjusted to 3 with 2N HCl to precipitate a large amount of solid, which was then filtered and the cake was washed with water (40 ml). The cake was drained and dried to obtain 1.61 g of a light gray solid compound 6-chloro-4-formylnicotinic acid (B18-2) (1.61 g, yield: 34.2%).

[0474] LC-MS, M / Z (ESI): 183.8[MH] - .

[0475] Step 2: Synthesis of 6-chloro-2-methyl-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one (B18-3)

[0476] [ka]

[0477] A suspension of 6-chloro-4-formylnicotinic acid (520 mg, 2.8 mmol) in glacial acetic acid (1.12 ml, 19.6 mmol) was added with 40% aqueous methylamine solution (0.36 ml, 3.22 mmol), a dioxane solution of hydrogen chloride (4 M, 0.77 ml, 3.08 mmol), and sodium triacetoxyborohydride (891 mg, 4.2 mmol) under nitrogen gas, and the mixture was stirred at room temperature for 18 h, and then at 60° C. for 5 h. Further, 40% aqueous methylamine solution (0.25 ml, 2.24 mmol) and sodium triacetoxyborohydride (475 mg, 2.24 mmol) were added at room temperature, and the reaction was continued at room temperature for 18 h. Ethyl acetate (30 ml) was added, washed with 1M sodium carbonate solution (30 ml), washed with water (30 ml), washed with saturated saline solution (30 ml), dried over anhydrous sodium sulfate, and concentrated to obtain compound 6-chloro-2-methyl-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one (B18-3) (light yellow solid, 312.2 mg, yield: 61%).

[0478] LC-MS, M / Z (ESI): 183.0[M+H] + .

[0479] Step 3: Synthesis of 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one (I-18)

[0480] [ka]

[0481] The synthesis of compound I-18 was carried out according to the synthesis of compound I-1, with intermediate B18-3 replacing A1-2.

[0482] 1H NMR (400 MHz, DMSO) δ 8.58 (d, 1H), 8.12 (d, 1H), 7.90 (d, 1H), 7.58 (s, 1H), 4.88 (d, 1H), 4.41 (dd, 2H), 3.63 (s, 4H), 3.34 (s, 1H), 3.01 (s, 3H), 2.19 (td, 1H), 2.15-1.99 (m, 5H), 1.09-1.01 (m, 1H), 0.90 (d, 1H).

[0483] LC-MS, M / Z (ESI): 440.2[M+H] + .

[0484] Example 19: Preparation of 3'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-6'-methylspiro[cyclopropane-1,5'-pyrrolo[3,4-b]pyridin]-7'(6'H)-one (I-19)

[0485] The synthetic route to the target compound I-19 is as follows:

[0486] [ka]

[0487] The synthesis of compound I-19 was based on compound I-1, with intermediate A3 replacing A1-2.

[0488] 1 H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 7.98 (d, 1H), 7.72 (s, 1H), 7.22 (s, 1H), 3.94-3.91 (m, 2H), 3.81-3.76 (m, 2H), 3.25 (s, 3H), 2.07-2.04 (m, 3H), 1.73-1.62 (m, 6H), 1.37 (s, 1H), 1.28-1.23 (m, 3H), 1.19-1.17(m, 1H).

[0489] LC-MS, M / Z (ESI): 466.2[M+H] + .

[0490] Example 20: Preparation of 7-(6-(3-fluoro-3-methylazetidine-1-carbonyl)-1a,2-dihydro-1H-cyclopropa[c][1,8]naphthyridin-3(7bH)-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-20)

[0491] The synthetic route of the target compound I-20 is as follows:

[0492] [ka]

[0493] Step 1: 1a,2,3,7b-Tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate methyl (B20-1)

[0494] [ka]

[0495] 3-(4-Methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-methyl carboxylate (35g, 108mmol) was placed in a one-neck flask (500ml), trifluoroacetic acid (83ml) was added, and the mixture was stirred at 60°C for 4h to react. After the reaction was completed, the trifluoroacetic acid was removed by spin distillation, the residue was slowly added to water (500ml), the pH was adjusted to 1 with concentrated hydrochloric acid, extracted with ethyl acetate (300ml x 3), the aqueous phase was further adjusted to pH 9 with sodium carbonate powder, extracted with dichloromethane (500ml x 3), the organic phase was combined, dried by adding anhydrous sodium sulfate, filtered, and concentrated to obtain 1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-methyl carboxylate (20.3g, yield: 92%).

[0496] LC-MS, M / Z (ESI): 205.1 [M+H] + .

[0497] Step 2: Methyl 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate (B20-2)

[0498] [ka]

[0499] Under the protection of nitrogen gas, 1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-methyl carboxylate (19.4 g, 95 mmol), cesium carbonate (77 g, 237 mmol), 7-bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (23.83 g, 104 mmol), bis(dibenzylideneacetone)palladium (8.7 g, 9.5 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (5.5 g, 19.5 mmol) were added to dioxane (200 ml) and reacted with stirring at 85 ° C. for 12 h. The reaction solution was filtered, and the filtrate was concentrated to obtain a crude product. The crude product was added with ethyl acetate (90 ml) and petroleum ether (180 ml), stirred for 2 h to form a slurry, and filtered to give methyl 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate (44 g, crude product).

[0500] LC-MS, M / Z (ESI): 352.1 [M+H] + .

[0501] Step 3: 3-(2-Methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (B20-3)

[0502] [ka]

[0503] The crude product, methyl 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylate (41.3 g, 118 mmol), was dissolved in a mixture of tetrahydrofuran (300 ml), methanol (60 ml) and water (60 ml), and lithium hydroxide monohydrate (24.66 g, 588 mmol) was added and stirred at room temperature for 12 hours. After stirring and reaction completion, the mixture was concentrated to obtain a residue, which was dissolved in water (300 ml) and extracted with ethyl acetate (300 ml x 3). The aqueous phase was further stirred and concentrated hydrochloric acid was added dropwise to adjust the pH to 1, and the mixture was filtered to obtain 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (27 g, 2-step yield: 87%).

[0504] LC-MS, M / Z (ESI): 338.1 [M+H] + .

[0505] Step 4: 7-(6-(3-fluoro-3-methylazetidine-1-carbonyl)-1a,2-dihydro-1H-cyclopropa[c][1,8]naphthyridin-3(7bH)-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-20)

[0506] [ka]

[0507] Under the protection of nitrogen gas, 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (280 mg, 830 μmol), 3-fluoro-3-methyl-azetidine hydrochloride (148 mg, 1.18 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (316 mg, 830 μmol) and N,N-diisopropylethylamine (107 mg, 830 μmol) were added to N,N-dimethylformamide (5 ml) and reacted at 25 ° C. for 8 h under the protection of nitrogen gas. After the reaction was completed, water (50 ml) was added to the reaction solution, and then extracted with ethyl acetate (60 ml x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by high performance liquid chromatography. The separation method was (column: Phenomenex Synergi C 18 150×50 mm×10 μm; solvent: A=water+0.1 volume percent ammonia bicarbonate (99%), B=acetonitrile; gradient: 16% to 46%, 10 min) to give the target compound 7-(6-(3-fluoro-3-methylazetidine-1-carbonyl)-1a,2-dihydro-1H-cyclopropa[c][1,8]naphthyridin-3(7bH)-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-20) (218 mg, yield: 62.9%).

[0508] 1H NMR (400 MHz, CDCl3) δ 8.23 ​​(d, J = 2.0 Hz, 1H), 7.96 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.52-6.54 (m, 2H), 4.39-4.46 (m, 1.11-1.16 (m, 2H).

[0509] LC-MS, M / Z (ESI): 409.1 [M+H] + .

[0510] Example 21: Preparation of 7-(6-(3,3-difluoropyrrolidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-21)

[0511] The synthetic route to the target compound I-21 is as follows:

[0512] [ka]

[0513] 3-(2-Methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.6 mmol), 3,3-difluoropyrrolidine (62 mg, 0.7 mmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (10 ml), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.7 mmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After the reaction was completed, the mixture was diluted with water (20 ml) and extracted three times with ethyl acetate (90 mL). The organic phases were combined, washed with saturated saline (30 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (column: Phenomenex C 18 75×30 mm×3 μm; solvents: A=water+1 volume percent formic acid (99%)+water, B=acetonitrile; gradient: 28% to 58%, 7 min) to give 7-(6-(3,3-difluoropyrrolidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-21) (170 mg, yield: 50.4%).

[0514] 1 H NMR (400 MHz, CDCl3) δ 8.14 (d, 1H), 7.91 (s, 1H), 7.62 (d, 1H), 6.70 (s, 1H), 6.57 (d, 1H), 3.88-3.91 (m, 3H), 3.65-3.68 (m, 3H), 3.48 (s, 3H), 2.40-2.45(m, 2H), 2.20-2.23(m, 1H), 2.06-2.08(m, 1H), 1.04-1.09(m, 2H).

[0515] LC-MS, M / Z (ESI): 427.2 [M+H]+ .

[0516] Example 22: Preparation of 2-methyl-7-(6-(morpholine-4-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-22)

[0517] The synthetic route to the target compound I-22 is as follows:

[0518] [ka]

[0519] 3-(2-Methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.6 mmol), morpholine (62 mg, 0.7 mmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (10 ml), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.7 mmol) was added, and the reaction solution was reacted at 25°C for 1 h. After the reaction was completed, the mixture was diluted with water (20 mL) and extracted three times with ethyl acetate (90 mL). The organic phases were combined, washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (column: Phenomenex C 1875×30 mm×3 μm; solvent: A=water+1 volume percent formic acid (99%)+water, B=acetonitrile; gradient: 28% to 58%, 7 min) and lyophilized to give 2-methyl-7-(6-(morpholine-4-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-22) (170 mg, yield: 50.4%).

[0520] 1 H NMR (400 MHz, CDCl3) δ 8.08 (d, 1H), 7.71 (d, 1H), 7.58 (dd, 1H), 6.55-6.50 (d, 2H), 3.95 (d, 1H), 3.71-3.63 (m, 12H), 2.01-2.06 (m, 2H), 1.18-1.13 (m, 2H).

[0521] LC-MS, M / Z (ESI): 407.2 [M+H] + .

[0522] Example 23: Preparation of 7-(6-(3-(difluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-23)

[0523] The synthetic route to the target compound I-23 is as follows:

[0524] [ka]

[0525] 3-(2-Methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.6 mmol), 3-(difluoromethyl)piperidine (96 mg, 0.7 mmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (10 ml), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.7 mmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After the reaction was completed, the mixture was diluted with water (20 mL) and extracted three times with ethyl acetate (90 mL). The organic phases were combined, washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (column: Phenomenex C 18 75×30 mm×3 μm; solvents: A=water+1 volume percent formic acid (99%)+water, B=acetonitrile; gradient: 28% to 58%, 7 min) to give 7-(6-(3-(difluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-23) (144 mg, yield: 53.5%).

[0526] 1 H NMR (400 MHz, CDCl3) δ 8.07 (t, 1H), 7.69 (t, 1H), 7.58 (d, 1H), 6.55-6.50 (m, 2H), 5.69 (t, 1H), 3.95 (d, 1H), 3.70 (d, 1H), 3.63 (s, 3H), 3.01 (b, 2H), 2.09-2.01 (m, 4H), 1.60 (b, 1H), 1.58-1.49 (m, 4H), 1.18 -1.12 (m, 2H).

[0527] LC-MS, M / Z (ESI): 455.2 [M+H] + .

[0528] Example 24: Preparation of 7-(6-(3,3-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-24)

[0529] The synthetic route to the target compound I-24 is as follows:

[0530] [ka]

[0531] 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 593 μmol), 3,3-difluoropiperidine (108 mg, 889 μmol) and N,N-diisopropylethylamine (153 mg, 1.18 mmol) were dissolved in N,N-dimethylformamide (10 ml), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (271 mg, 711 μmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After completion of the reaction, the mixture was diluted with water (20 mL), extracted with ethyl acetate (10 ml) three times, and the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (DCM / MeOH (v / v) = 15 / 1) to obtain the target compound 7-(6-(3,3-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-24) (120 mg, yield: 46%).

[0532] 1 H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 2.2 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 6.55 (dd, J = 7.6, 2.0 Hz, 1H), 6.51 (d, J = 1.5 Hz, 1H), 3.94 (d, J = 11.1 Hz, 1H), 3.79 (d, J = 9.2 Hz, 2H), 3.70 (dd, J = 10.9, 1.4 Hz, 2H), 3.63 (s, 4H), 2.14-2.04 (m, 4H), 1.89-1.81 (m, 2H), 1.19-1.10 (m, 2H).

[0533] LC-MS, M / Z (ESI): 441.1 [M+H] + .

[0534] Example 25: Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-(methyl-d3)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-25)

[0535] The synthetic route to the target compound I-25 is as follows:

[0536] [ka]

[0537] The synthesis of compound I-25 was performed according to compound I-3, with deuterated iodomethane replacing iodomethane. LC-MS, M / Z (ESI): 444.2[M+H] + .

[0538] 1H NMR (400 MHz, DMSO) δ 8.03 (d, 1H), 7.80 (s, 1H), 7.61 (d, 1H), 6.68 (d, 1H), 6.58 (dd, 1H), 3.90 (d, 1H), 3.66-3.59(m, 5H), 2.18-2.16(m, 1H), 2.08-1.99(m, 5H), 1.06 (t, 2H)

[0539] The product I-25 was resolved by SFC (chromatographic column: Chiralpak AD-3 50×4.6 mm ID, 3 μm, mobile phase: mobile phase A: CO2, mobile phase B: IPA+ACN (0.05% by volume of DEA); isocratic elution: 50% by volume of IPA+ACN (0.05% by volume of DEA) (in CO2), flow rate: 3 mL / min; detector: PDA, column temperature: 35° C.; column pressure: 100 Bar). Isomer (I-25A) (RT=0.764 min) and isomer (I-25B) (RT=1.702 min) were obtained.

[0540] [ka]

[0541] Example 26: Preparation of 2-methyl-7-(6-(3-(trifluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-26)

[0542] The synthetic route to the target compound I-26 is as follows:

[0543] [ka]

[0544] 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 593 μmol), 3-trifluoromethylpiperidine (136 mg, 889 μmol) and N,N-diisopropylethylamine (153 mg, 1.18 mmol) were dissolved in N,N-dimethylformamide (10 ml), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (271 mg, 711 μmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After completion of the reaction, it was diluted with water (20 ml) and extracted with ethyl acetate (10 ml) three times, the organic phases were combined, washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified by column chromatography (DCM / MeOH (v / v) = 15 / 1) to give the target compound (I-26) (130 mg, yield: 50%).

[0545] 1 H NMR (400 MHz, CDCl3) δ 8.06 (t, J = 2.0 Hz, 1H), 7.68 (t, J = 1.9 Hz, 1H), 7.58 (dd, J = 7.6, 0.5 Hz, 1H), 6.54 (dd, J = 7.6, 2.0 Hz, 1H), 6.51 (d, J = 1.4 Hz, 1H), 3.94 (d, J = 11.0 Hz, 1H), 3.70 (d, J = 10.4 Hz, 1H), 3.63 (s, 3H), 2.98 (s, 2H), 2.32 (s, 1H), 2.09 (ddd, J = 11.7, 10.3, 7.3Hz, 3H), 1.84 (s, 1H), 1.68 (d, J = 10.3 Hz, 1H), 1.66-1.45 (m, 3H), 1.19-1.10 (m, 2H).

[0546] LC-MS, M / Z (ESI): 473.1 [M+H] + .

[0547] Example 27: Preparation of 7-(6-(3-fluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-27)

[0548] The synthetic route to the target compound I-27 is as follows:

[0549] [ka]

[0550] 3-(2-Methyl-3-oxy-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.59 mmol), 3-fluoropiperidine hydrochloride (83 mg, 0.59 mmol), N,N-diisopropylethylamine (307 mg, 2.37 mmol), and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (271 mg, 0.71 mmol) were added to N,N-dimethylformamide (6 ml) and the mixture was stirred at room temperature for 2 h. The reaction solution was added to water (30 ml), and then extracted with dichloromethane (50 ml x 2). The organic phases were combined, washed with saturated saline (30 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate:methanol (V / V) = 20:1) to obtain compound 7-(6-(3-fluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-27) (196 mg, yield: 78.4%).

[0551] 1H NMR (400 MHz, DMSO) δ 7.96 (d, 1H), 7.75 (d, 1H), 7.62 (d, 1H), 6.68 (d, 1H), 6.59 (ddd, 1H), 4.77 (d, 1H), 3.91 (d, 2H), 3.65 (dd, 1H), 3.49 (s, 5H), 3.15 (s, 1H), 2.19 (dt, 1H), 2.08 (dd, 1H), 1.90 (d, 2H), 1.77-1.66 (m, 1H), 1.54 (s, 1H), 1.12-1.03 (m, 2H).

[0552] LC-MS, M / Z (ESI): 423.3 [M+H] + .

[0553] Example 28: Preparation of 7-(6-(6-azaspiro[2.5]octane-6-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-28)

[0554] The synthetic route to the target compound I-28 is as follows:

[0555] [ka]

[0556] 3-(2-Methyl-3-oxy-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (120 mg, 0.36 mmol), 6-azaspiro[2.5]octane (40 mg, 0.36 mmol), N,N-diisopropylethylamine (184 mg, 1.42 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (162 mg, 0.43 mmol) were added to N,N-dimethylformamide (5 mL) and reacted at room temperature for 2 h. The reaction solution was added to water (30 ml), and then extracted with dichloromethane (50 ml x 2). The organic phases were combined, washed with saturated saline (30 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (dichloromethane:methanol (V / V) = 30:1) to obtain compound 7-(6-(6-azaspiro[2.5]octane-6-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-28) (82 mg, yield: 53.6%).

[0557] 1 H NMR (400 MHz, DMSO) δ 7.98 (d, 1H), 7.77 (d, 1H), 7.61 (d, 1H), 6.67 (d, 1H), 6.59 (dd, 1H), 3.90 (d, 1H), 3.64 (dd, 2H), 3.48 (s, 5H), 2.19 (dd, 1H), 2.07 (dd, 1H), 1.35 (s, 4H), 1.25 (dd, 1H), 1.06 (t, 2H), 0.34 (s, 4H).

[0558] LC-MS, M / Z (ESI): 431.2 [M+H] + .

[0559] Example 29: Preparation of 7-(6-(3-azabicyclo[3.1.0]hexane-3-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-29)

[0560] The synthetic route to the target compound I-29 is as follows:

[0561] [ka]

[0562] 3-(2-Methyl-3-oxy-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.59 mmol) and 3-azabicyclo[3.1.0]hexane (49 mg, 0.59 mmol), N,N-diisopropylethylamine (307 mg, 2.37 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were added to N,N-dimethylformamide (5 ml) and reacted at room temperature for 2 hours. was added to water (30 ml), then extracted with dichloromethane (50 ml x 2), the organic phases were combined, washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (ethyl acetate:methanol (V / V) = 25:1) to obtain compound 7-(6-(3-azabicyclo[3.1.0]hexane-3-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-29) (158 mg, yield: 66.1%).

[0563] 1H NMR (400 MHz, DMSO) δ 8.06 (d, 1H), 7.82 (d, 1H), 7.61 (d, 1H), 6.68 (d, 1H), 6.57 (dd, 1H), 3.93 (dd, 2H), 3.80-3.61 (m, 2H), 3.48 (s, 3H), 3.43 (d, 2H), 2.18 (dd, 1H), 2.11-2.03 (m, 1H), 1.54 (d, 2H), 1.11-0.99 (m, 2H), 0.64 (dd, 1H), 0.07 (s, 1H).

[0564] LC-MS, M / Z (ESI): 403.2 [M+H] +

[0565] Example 30: Preparation of 7-(6-((R)-3-(fluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-30)

[0566] The synthetic route of the target compound I-30 is as follows:

[0567] [ka]

[0568] 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.6 mmol), (R)-3-(fluoromethyl)piperidine (70 mg, 0.6 mmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (10 ml), and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.7 mmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After the reaction was completed, the mixture was diluted with water (20 mL) and extracted three times with ethyl acetate (90 mL). The organic phases were combined, washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (column: Phenomenex C 18 75×30 mm×3 μm; solvents: A=water+1 volume percent formic acid (99%)+water, B=acetonitrile; gradient: 28% to 58%, 7 min) to give 7-(6-((R)-3-(fluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-30) (183 mg, yield: 70.7%).

[0569] 1 H NMR (400 MHz, CDCl3) δ 8.07 (t, 1H), 7.69 (s, 1H), 7.58 (d, 1H), 6.56-6.54 (m, 1H), 6.45 (t, 1H), 4.36 (d, 3H), 3.95 (d, 1H), 3.69 (d, 1H), 3.63 (s, 3H), 3.01 (b, 2H), 2.09-1.78 (m, 6H), 1.60 (b, 1H), 1.40 (b, 1H), 1.19 -1.10 (m, 2H).

[0570] LC-MS, M / Z (ESI): 437.2 [M+H] + .

[0571] Example 31: Preparation of 7-(6-((S)-3-(fluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-31)

[0572] [ka]

[0573] 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridine-6-carboxylic acid (200 mg, 0.6 mmol), (S)-3-(fluoromethyl)piperidine (70 mg, 0.6 mmol) and N,N-diisopropylethylamine (155 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (10 ml), and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (270 mg, 0.7 mmol) was added, and the reaction solution was reacted at 25 ° C. for 1 h. After the reaction was completed, the mixture was diluted with water (20 ml) and extracted three times with ethyl acetate (90 mL). The organic phases were combined, washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated by reversed-phase high-performance liquid chromatography (column: Phenomenex C 1875×30 mm×3 μm; solvents: A=water+1 volume percent formic acid (99%)+water, B=acetonitrile; gradient: 28% to 58%, 7 min) to give 7-(6-((S)-3-(fluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-31) (white solid, 206 mg, yield: 79.6%).

[0574] 1 H NMR (400 MHz, CDCl3) δ 8.07 (t, 1H), 7.69 (s, 1H), 7.58 (d, 1H), 6.56-6.54 (m, 1H), 6.45 (t, 1H), 4.36 (d, 3H), 3.95 (d, 1H), 3.69 (d, 1H), 3.63 (s, 3H), 3.01 (b, 2H), 2.09-1.78 (m, 6H), 1.60 (b, 1H), 1.40 (b, 1H), 1.19-1.10 (m, 2H).

[0575] LC-MS, M / Z (ESI): 437.2 [M+H] + .

[0576] Example 32: Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-32)

[0577] The synthetic route to the target compound I-32 is as follows:

[0578] [ka]

[0579] Step 1: Synthesis of 7-bromo-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B32-1)

[0580] [ka]

[0581] 7-Bromo-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B3-3) (100mg, 467umol) was dissolved in N,N-dimethylformamide (5ml), cesium carbonate (457mg, 1.40mmol) was added, and ethyl iodide (219mg, 1.40mmol) was added under the protection of nitrogen gas at 0-10℃. After the addition was completed, the reaction was carried out at 25℃ for 2h, and the reaction solution was poured into water (10ml), extracted with ethyl acetate (20ml×3), and the organic phase was combined, washed with saturated saline (20mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 7-bromo-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (B32-1) (113mg, yield: 99.4%).

[0582] LC-MS, M / Z (ESI): 242.1 [M+H] + .

[0583] Step 2: Synthesis of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-32)

[0584] [ka]

[0585] Under the protection of nitrogen gas, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropa[c][1,8]naphthyridin-6-yl)methanone (145mg, 493umol), cesium carbonate (201mg, 477umol), 7-bromo-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (60.0mg, 247umol), bis(dibenzylideneacetone)palladium (22.6mg, 24.7umol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (28.5mg, 49.3umol) were added to 1,4-dioxane (10ml) and reacted at 100℃ for 2h with stirring. After the reaction was completed, the reaction solution was poured into water (10 ml) and extracted with ethyl acetate (10 ml x 3). The organic phases were combined, washed with saturated saline (10 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then purified by preparative high performance liquid chromatography (column: Phenomenex Synergi C 18 150×25mm×5um; solvent: A=water+0.1 volume percent formic acid (99%), B=acetonitrile; gradient: 30% to 60% B, 7 min) to give compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl)-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-32) (80.0 mg, yield: 71.2%).

[0586] 1 H NMR (400 MHz, DMSO d6) δ = 8.04 (d, 1H), 7.82 (d, 1H), 7.63 (d, 1H), 6.72 (s, 1H), 6.57-6.60 (m, 1H), 3.87-3.93 (m, 3H), 3.61-3.67 (m, 5H), 2.15-2.18 (m, 1H), 2.01-2.09 (m, 5H), 1.28 (t, 3H), 1.06-1.09 (m, 2H).

[0587] Test Example 1: 15-PGDH enzyme inhibition test by compounds 15-PGDH (R&D Systems, Catalog No.: 5660-DH-010) was prepared in Assay Buffer (50 mM Tris-HCl, pH: 7.5, 0.01 volume percent Tween 20) to twice the final concentration, i.e., 30 nM. Then, 8 μl / well was added to a 384 white plate (Cisbio Bioassays, Catalog No.: 66PL384025). Negative control wells were set up and only Assay Buffer was added without enzyme. Then, compounds were diluted 3-fold to 10 concentrations using Assay Buffer, starting from 4 times the final concentration, i.e., 4000 nM. 4 μl / well was added to the above white plate, mixed evenly, centrifuged at 1000 rpm for 1 minute, and incubated at 25°C for 10 minutes. At the same time, positive control wells (only 15-PGDH was added) and negative control wells (no 15-PGDH added) were set up. In addition, NAD was detected using Assay Buffer. + A mixed solution of NAD (Select, Catalog No. S2518) and PGE2 (R&D Systems, Catalog No. 2296 / 10) was prepared using assay buffer. + and PGE2 were prepared at 4 times the final concentration, i.e., 2 mM and 0.12 mM. Then, 4 μl / well was added to the above white plate, mixed evenly, centrifuged at 1000 rpm for 1 minute, and incubated at 25°C for 30 minutes to react. The device TECAN SPARK 20M was used for detection at an excitation wavelength of 340 nm and an emission wavelength of 485 nm. The data was fitted with 4 parameters using GraphPad Prism 8.0 to obtain the IC 50 values ​​were calculated.

[0588] [Table 1]

[0589] The experimental results showed that the compounds of the present invention had significant inhibitory effects on 15-PGDH.

[0590] Test Example 2: Effect of compounds on PGE2 levels in A549 cell supernatant A549 cells (Procell, Wuhan) were cultured in F12K + 10% FBS, and cells in logarithmic phase with good cell condition were selected for the experiment, digested and counted, and the cells were seeded into a 24-well plate at 8000 cells / well. The cells were cultured overnight in a 37°C, 5% CO2 incubator. After the cells attached to the wall, the medium was replaced with one containing 0.5% FBS and treated for about 10 hours, and IL-1β (final concentration: 20ng / mL, 1mL / well) was added to each well, and a control group (no IL-1β was added to the control group) was set at the same time. After stimulation with IL-1β for about 24 hours, the cell culture medium was removed by aspirating from each well, and each well was gently washed with fresh medium containing 0.5% FBS, and then 400μL of medium containing each concentration of compound (20nM and 2500nM) was added to each well and treated for about 12 hours. The supernatant was collected and PGE2 was detected using an ELISA kit (R&D Systems, Cat. No.: KGE004B).

[0591] [Table 2]

[0592] The experimental results show that the compounds of the present invention can significantly increase the production of PGE2.

[0593] Test Example 3: Efficacy test in a mouse IPF prevention model Male mice were adaptively raised for 1-2 weeks, and after reaching a standard body weight (25 g), a predetermined amount of bleomycin was administered to induce an IPF model (idiopathic pulmonary fibrosis model). On the day of modeling, the animals were randomly divided into model and treatment groups according to their body weights. The treatment group was administered nintedanib (60 mg / kg, once a day (qd)) and the compound I-3B of the present invention (2.5 mg / kg, twice a day (bid)), and oral intragastric administration was started every day. The solvent control group was administered blank solvent for 21 consecutive days. During the administration period, the body weight was measured every 3 days. At the end of the last day of administration, the animals were euthanized, the lungs were removed from the thyroid cartilage (no need to perfuse), and the lungs were slowly perfused with 10% formalin until both lungs were filled. After the main trachea was ligated, the left lung was fixed with 5-10 times the tissue volume of 10% formalin. The left lung was subjected to paraffin tissue sectioning, HE staining, Masson's method, and the left lung was subjected to 10-20 minutes of ... Trichrome staining was performed, and panoramic scanning of sections was performed for pathological analysis using a Hamamatsu NanoZoomer Digital Pathology (S210) slide scanner.

[0594] [Table 3]

[0595] [Table 4]

[0596] The experimental results show that the compounds of the present invention can significantly reduce the degree of fibrosis in a murine IPF prevention model.

[0597] Test Example 4: Drug efficacy experiment in a mouse IPF treatment model Male mice were adaptively raised for 1-2 weeks, and after reaching a standard body weight (25g), a predetermined amount of bleomycin was administered to induce an IPF model (idiopathic pulmonary fibrosis model). On the day of modeling, the animals were randomly divided into model groups and administration groups according to their body weight, among which the administration group was administered nintedanib (60mg / kg, qd), low dose of the compound I-3B of the present invention (1mg / kg, bid) and high dose of the compound I-3B of the present invention (2.5mg / kg, bid), and oral intragastric administration was started daily from Day 7, and the solvent control group was administered blank solvent for 14 consecutive days. During the administration period, body weight was measured twice a week. At the end of the last day of treatment, the animals were euthanized, the lungs were removed from the thyroid cartilage (no need to perfuse), and the lungs were slowly perfused with 10% formalin until both lungs were filled. After ligating the main trachea, the lungs were fixed in 5-10 tissue volumes of 10% formalin. Paraffin tissue sections, HE staining, and Masson Trichrome staining of the left lung were performed, and panoramic scanning of the sections was performed for pathological analysis using a Hamamatsu NanoZoomer Digital Pathology (S210) slide scanner.

[0598] [Table 5]

[0599] [Table 6]

[0600] The experimental results show that the compounds of the present invention can significantly reduce the degree of fibrosis in a mouse IPF treatment model.

[0601] Test Example 5: Experiment on regenerative effect after liver resection in mice Eight-week-old male C57BL / 6J mice (20–24 g) were anesthetized and fixed with their abdomens facing upward. The surgical site was shaved and disinfected with iodophor. The abdominal lateral opening was about 1.5–2 cm, and the abdominal wall arteries on both sides were clamped with hemostatic clips. After opening the abdominal cavity, each liver lobe was separated, and the hepatic hilum of the liver lobe that needed to be resected was tied with surgical wire. After the color darkened, the left outer and middle lobes of the liver were resected. After washing the remaining blood in the abdominal cavity, the muscle layer and fur layer were sutured one layer at a time, and postoperative care was paid attention to. Administration began on the day of modeling, and eight animals were euthanized on the first and third days, respectively, and the intact liver tissue was removed and weighed, and compared with the model group to evaluate the effect of the drug on promoting liver regeneration.

[0602] The experimental results show that the compounds of the present invention can significantly promote liver regeneration.

[0603] Test Example 6: Pharmacokinetics in mice The pharmacokinetic properties of the compounds of the present invention in mice were determined with reference to the experimental methods described below.

[0604] Three male CD-1 mice were used and intragastrically administered at a dose of 10 mg / kg. The solvent was 5% DMSO + 10% Solutol + 85% Saline. They were fasted overnight, and blood was collected before administration and at 15, 30 min and 1, 2, 4, 6, 8, and 24 h after administration. The blood samples were centrifuged at 6800 g for 6 min at 2-8 °C, and the plasma was collected and stored at -80 °C. At each time point, 10 μL of plasma was collected, and 200 μL of methanol containing 100 ng / mL internal standard was added, vortexed to mix uniformly, and then centrifuged at 18000 rpm at 2-8 °C for 7 min. 200 μL was taken and transferred to a 96-well sample plate, and LC-MS / MS quantitative analysis was performed. The main pharmacokinetic parameters were analyzed by the noncompartmental model of WinNonlin 7.0 software.

[0605] [Table 7]

[0606] The experimental results show that the compounds of the present invention exhibit good pharmacokinetic properties in mice.

[0607] Test Example 7: Drug efficacy against IBD in mice Six to eight week old female C57BL / 6 mice were divided into five groups, G1 to G5 were normal control group, model control group, positive control group, compound I-3B low dose group and compound I-3B high dose group, respectively. Mice in groups G2 to G6 were given 2% DSS aqueous solution on days 0 to 6, normal water on days 0 to 10, and administered vehicle / positive substance / test substance on days 0 to 9. On day 10, they were euthanized and autopsied, and intestinal weight (CW), intestinal length (CL) were measured, and intestinal tissue (BW) was subjected to histopathological examination. The test results showed that compared with the animals in the G2 model group, the weight of the animals in the G3-positive control group (cyclosporine CsA 25 mg / kg-qd) was significantly increased, the DAI of the model animals was significantly decreased, the CL was significantly increased, and the CW, CL / CW / BW and CL / CW were significantly decreased. The results of the histopathological examination of the colon tissues of the model animals showed that the scores of inflammatory cell infiltration and tissue damage were decreased, but there was no significant difference. The weights of the animals in the G4-compound I-3B (2.5 mg / kg-bid) and G5-compound I-3B (5 mg / kg-bid) groups were both increased, where the weight of the G5 animals was significantly increased. The DAI of the animals was all significantly decreased, the CL was all significantly increased, and the CW, CL / CW / BW and CL / CW were all significantly decreased. The results of the histopathological examination of the colon tissues showed that the scores of inflammatory cell infiltration and tissue damage were all significantly decreased.

[0608] [Table 8]

[0609] The experimental results show that compound I-3B (2.5 mg / kg and 5 mg / kg) can significantly improve the IBD symptoms and tissue damage in mice, and the therapeutic effect is higher than that of the positive group.

[0610] Although the embodiments of the present invention have been shown and described above, it should be understood that the above embodiments are illustrative and are not to be construed as limiting the present invention, and that changes, modifications, substitutions and variations of the above embodiments may be made by those skilled in the art within the scope of the present invention.

Claims

1. A heterocyclic compound represented by formula I, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof. 【Chemistry 1】 (however, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represents a ring atom, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N, NH, O, S, or CH 2 , CH or C; R 1 and R 2 are each independently hydrogen, C 1 ~C 6 Alkyl or C 3 ~C 8 is cycloalkyl, Or, R 1 and R 2 together with the N atom to which they are attached form a 3- to 11-membered heterocycloalkyl, wherein said 3- to 11-membered heterocycloalkyl further comprises zero, one or more R 1-1 and when there are a plurality of substituents, the substituents may be the same or different, Each R 1-1 are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; R a and R b are each independently halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy or haloC 1 ~C 6 is an alkoxy; m and n are each independently 0, 1, 2, or 3; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a ring atom, X 1 , X 2 , X 3 , X 4 and X 5 are each independently N, O, S, or CH 2 , CH or C; X 4 and X 5 The bond between is a single bond or a double bond, R 3 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; X 4 and X 5 The radical fragment formed by linking 【Chemistry 2】 In the above, A does not exist, or A and X 4 , X 5 the ring atoms together form a 3- to 11-membered heterocycloalkyl, a 5-membered heteroaromatic ring, or a 6-membered heteroaromatic ring, the heteroatoms being independently selected from one or more of N, O, and S; If A does not exist, then X 4 and X 5 are each independently R 4 Or R 5 is replaced by When A is present, said A may further comprise R 3-1 and R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, R 4 and R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; R 5 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally one or two R 5-1 an aminocarbonyl group substituted with 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Each of the R 5-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 It is an amino having an alkyl group.

2. The heterocyclic compound of formula I according to claim 1, its solvate, its pharma- ceutically acceptable salt, its solvate of its pharma- ceutically acceptable salt or its prodrug, characterized in that the heterocyclic compound of formula I satisfies one or more of the following conditions: ((1) The above R 1 and R 2 together with the N atom to which they are linked form a 3- to 11-membered heterocycloalkyl, the heterocycloalkyl being a monocyclic heterocycloalkyl, a bridged bicyclic heterocycloalkyl or a spiro bicyclic heterocycloalkyl; (2) The above R 1 and R 2 together with the N atom to which they are linked, the heteroatoms in the 3- to 11-membered heterocycloalkyl are one or more of N, O, or S, and the number is 1, 2, 3, or 4; (3) The above R 1 and R 2 together with the N atom to which they are linked, the 3- to 11-membered heterocycloalkyl formed is a 3- to 8-membered heterocycloalkyl; (4) R 1-1 In the above, the halogen and the haloC 1 ~C 6 The halogen and halo in alkyl are each independently F, Cl or Br, e.g., F; (5) R 1-1 In the above, 1 ~C 6 Alkyl and the haloC 1 ~C 6 In alkyl, C 1 ~C 6 each alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, for example, methyl; (6) R 4 and R 5 wherein each halogen is independently F, Cl or Br, for example F; (7) R 4 and R 5 In the above, optionally one or two C 1 ~C 6 In the aminocarbonyl group having an alkyl group, 1 ~C 6 each alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, for example, methyl; (8) A and X 4 , X 5 In the 3- to 11-membered heterocycloalkyl which the ring atoms together form, the heterocycloalkyl is a monocyclic heterocycloalkyl or a spirocyclic bicyclic heterocycloalkyl; (9) A and X 4 , X 5 In the 3- to 11-membered heterocycloalkyl which the ring atoms together form, the 3- to 11-membered heterocycloalkyl is a 3- to 7-membered heterocycloalkyl; (10) A and X 4 , X 5 In a 3- to 11-membered heterocycloalkyl, the ring atoms together form a heterocycloalkyl having 1, 2, 3, or 4 heteroatoms; (11) A and X 4 , X 5 the number of heteroatoms in the 5-membered or 6-membered heteroaromatic ring formed by the ring atoms together is 1, 2, 3 or 4; (12) A is present, and the A further comprises R 3-1 When substituted by R 3-1 The number of is two, (13) R 3-1 In the above, the halo C 1 ~C 6 halo in alkyl is F, Cl or Br, for example F; (14) R 3-1 In the above, 1 ~C 6 Alkyl, the haloC 1 ~C 6 Alkyl and the C 1 ~C 6 In deuterated alkyl, C 1 ~C 6 each alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, for example, methyl or ethyl; (15) R 3-1 In the above, 3 ~C 8 The cycloalkyl of cycloalkyl is a monocyclic cycloalkyl, (16) R 3-1 In the above, 3 ~C 8 cycloalkyl of cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; (17) 【Chemistry 3】 is a phenyl or a "six-membered heteroaromatic ring having one, two or three heteroatoms selected from one or more of N, O and S", such as a pyridine ring; The phenyl is preferably 【Chemistry 4】 and The pyridine ring is preferably 【Chemistry 5】 and (18) 【Chemistry 6】 is "a 6-membered heteroalkyl ring substituted with cyclopropane, in which the number of heteroatoms is one and the heteroatom is selected from N and O" or "a 6-membered heteroalkyl ring substituted with cyclopropane, in which the number of heteroatoms is one and the heteroatom is selected from N", e.g., a pyridine ring.

3. The heterocyclic compound of formula I according to claim 2, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof, characterized in that the heterocyclic compound of formula I satisfies one or more of the following conditions: ((1) The 3- to 8-membered heterocycloalkyl is a monocyclic 3- to 6-membered heterocycloalkyl, a bridged bicyclic 6- to 8-membered heterocycloalkyl, or a spiro bicyclic 8-membered heterocycloalkyl, in which the heteroatoms are N and / or O, and the number is 1 or 2, such as azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolidinyl-fused-cyclopropyl, oxaazaspiro[2.5]octyl, azaspiro[2.5]octyl, or octahydrocyclopenta[c]pyrrolidinyl; (2) The 3- to 8-membered heterocycloalkyl may further include halogen and / or haloC 1 ~C 6 is substituted with alkyl, (3) R 1-1 In the above, the halo C 1 ~C 6 Alkyl is trifluoromethyl, difluoromethyl or monofluoromethyl, preferably 【Chemistry 7】 and (4) R 4 and R 5 In the above, optionally one or two C 1 ~C 6 The aminocarbonyl groups having an alkyl group each independently 【Chemistry 8】 and (5) A and X 4 , X 5 In the 3- to 11-membered heterocycloalkyl, the ring atoms together form a monocyclic 3- to 6-membered heterocycloalkyl or a spirocyclic bicyclic 7-membered heterocycloalkyl, the heteroatoms are independently N and / or O and may be 1, 2 or 3 in number, e.g., pyrrolidinyl or azaspiro[2.4]heptyl; (6) The above A and X 4 , X 5 In the 5-membered or 6-membered heteroaromatic ring formed by the ring atoms together, the heteroatoms are N and may be 1, 2 or 3 in number, for example a pyridine ring, a pyrimidine ring or a triazole ring; (7) R 3-1 In the above, the halo C 1 ~C 6 Alkyl is 【Chemistry 9】 and (8) R 3-1 In the above, 1 ~C 6 Deuterated alkyl is -CD 3 and (9) 【Chemistry 10】 The ring in which is located is connected 【Chemistry 11】 For example, 【Chemistry 12】 It is.)

4. The heterocyclic compound represented by formula I according to claim 1, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof, characterized in that the heterocyclic compound represented by formula I satisfies (1) and / or (2). ((1) R 1 and R 2 together with the N atom to which they are linked form the group 【Chemistry 13】 (2) 【Chemistry 14】 teeth, 【Chemistry 15】 It is.)

5. The heterocyclic compound of formula I according to claim 1, its solvate, its pharma- ceutically acceptable salt, its solvate of its pharma- ceutically acceptable salt or its prodrug, characterized in that the heterocyclic compound of formula I satisfies one or more of the following conditions: ((1) Z 1 , Z 2 and Z 3 are each independently N, CH or C; (2) Z 4 and Z 5 are each independently N, NH, or CH 2 or CH, (3) R 1 and R 2 together with the N atom to which they are attached form a 3- to 11-membered heterocycloalkyl, wherein said 3- to 11-membered heterocycloalkyl further comprises zero, one or more R 1-1 is replaced by (4) R 1-1 is halogen, C 1 ~C 6 Alkyl or haloC 1 ~C 6 is alkyl, (5) R 4 and R 5 are independently halogen, cyano or optionally one or two C 1 ~C 6 an aminocarbonyl group having an alkyl group; (6) R 3-1 are independently oxo, C 1 ~C 6 Alkyl, haloC 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl or C 1 ~C 6 is a deuterated alkyl; (7) The solvate of the pharma- ceutically acceptable salt of the heterocyclic compound represented by formula I is a hydrate. (8) The heterocyclic compound represented by formula I has a structure represented by formula I-1 or I-2. 【Chemistry 16】

6. The heterocyclic compound represented by formula I according to any one of claims 1 to 5, characterized in that the heterocyclic compound represented by formula I is represented by any one of the following schemes. A heterocyclic compound represented by formula I according to any one of claims 1 to 5, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, or a prodrug thereof. Scheme 1: The heterocyclic compound represented by formula I is a compound represented by formula I′, 【Chemistry 17】 In formula I′, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represents a ring atom, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N or C; R 1 and R 2 are each independently hydrogen, C 1 ~C 6 Alkyl or C 3 ~C 8 is cycloalkyl, Or, R 1 and R 2 together with the N atom to which they are attached form a 3- to 11-membered heterocycloalkyl, where said C 3 ~C 8 The cycloalkyl or 3- to 11-membered heterocycloalkyl may further include R 1-1 is replaced by Each R 1-1 are each independently a halogen, a hydroxyl, an amino, a nitro, a cyano, a carbonyl, an oxo (=O), a carboxyl, or a C 1 ~C 6 Alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; R a and R b are each independently a halogen, a hydroxyl, an amino, a nitro, a cyano, a carbonyl, an oxo (=O), a carboxyl, or a C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy or haloC 1 ~C 6 is an alkoxy; m and n are each independently 0, 1, 2, or 3; X 1 , X 2 , X 3 , X 4 and X 5 each independently represents a ring atom, X 1 , X 2 , X 3 , X 4 and X 5 are each independently N or C; R 3 is halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy or haloC 1 ~C 6 is an alkoxy; X 4 and X 5 A fragment of a group formed by linking 【Chemistry 18】 In the above, A does not exist, or A and X 4 , X 5 the ring atoms together form a 3- to 11-membered heterocycloalkyl, a 5-membered heteroaromatic ring, or a 6-membered heteroaromatic ring, the heteroatoms being selected from one or more of N, O, and S; If A does not exist, then X 4 and X 5 are each independently R 4 Or R 5 is replaced by A is present, and A further comprises R 3-1 When substituted by R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, R 4 , R 5 and R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Scheme 2: In the heterocyclic compound represented by formula I, Z 1 , Z 2 and Z 3 are each independently N or C; Z 4 and Z 5 are each independently N, NH, or CH 2 or CH, R 1 and R 2 together with the N atom to which they are attached form a 3- to 11-membered heterocycloalkyl, wherein said 3- to 11-membered heterocycloalkyl further comprises zero, one or more R 1-1 is replaced by R 1-1 is halogen, C 1 ~C 6 Alkyl or haloC 1 ~C 6 is alkyl, m and n are 0; R 3 is hydrogen, R 4 and R 5 are independently halogen, cyano or optionally one or two C 1 ~C 6 an aminocarbonyl group having an alkyl group; R 3-1 are independently oxo, C 1 ~C 6 Alkyl, haloC 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl or C 1 ~C 6 is a deuterated alkyl; X 4 and X 5 A fragment of a group formed by linking 【Chemistry 19】 is defined as in claim 1, Scheme 3: The heterocyclic compound represented by formula I has a structure represented by formula II-1 below: 【Chemistry 20】 The definition of each group in formula II-1 is as described in Case 3-1 or Case 3-2 below. Case 3-1: X 4 and X 5 each independently represents a ring atom, X 4 and X 5 are each independently N, CH or C; A and X 4 , X 5 together form a 3- to 8-membered heterocycloalkyl, which further comprises R 3-1 and R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, Each R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1, Case 3-2: X 4 and X 5 each independently represents a ring atom, X 4 and X 5 are each independently N or C; A and X 4 , X 5 together form a 3- to 8-membered heterocycloalkyl, which further comprises R 3-1 and R 3-1 The substitution by may be one or more substitutions, and in the case of a plurality of substituents, said substituents may be the same or different, Each R 3-1 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1, Scheme 4: The heterocyclic compound represented by formula I has a structure represented by formula II-2 below: 【Chemistry 21】 The definition of each group in formula II-2 is as described in Case 4-1 or Case 4-2 below. Case 4-1: R 3 , R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 An alkylsulfonylamino group and optionally one or two C 1 ~C 6 selected from amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R a , R b , m and n are defined as in claim 1, Case 4-2: R 3 is halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 is an alkoxy; R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R a , R b , m and n are defined as in claim 1, Case 4-3: R 3 is H, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 is an alkoxy; R 4 and R 5 are each independently hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R a , R b , m and n are defined as in claim 1, Scheme 5: The heterocyclic compound represented by formula I has a structure represented by the following formulae III-1, III-2, III-3, III-4, III-5, III-6, III-7, and III-8, 【Chemical 22】 【Chemistry 23】 Here, Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are defined as in claim 1, Scheme 6: The heterocyclic compound represented by formula I has a structure represented by formula IV-1 below: 【Chemistry 24】 The definition of each group in formula IV-1 is as described in case 6-1 or case 6-2 below. Case 6-1: R 5-1 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1, Case 6-2: R 5-1 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 Alkylsulfonyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 selected from amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1, Scheme 7: The heterocyclic compound represented by formula I has a structure represented by formula IV-2 below: 【Chemistry 25】 The definition of each group in formula IV-2 is as described in case 7-1 or case 7-2 below. Case 7-1: R 5-1 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo (=O), carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, optionally having one or two C 1 ~C 6 Aminocarbonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1; R 4 does not exist, Case 7-2: R 5-1 is hydrogen, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 ~C 6 Alkyl, C 1 ~C 6 Deuterated alkyl, C 2 ~C 6 Alkynyl, HaloC 1 ~C 6 Alkyl, Hydroxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkylcarbonyl, C 1 ~C 6 Alkoxy, HaloC 1 ~C 6 Alkoxy, C 1 ~C 6 Alkoxycarbonyl, C 1 ~C 6 Alkylcarbonyloxy, C 1 ~C 6 Alkoxy C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxycarbonyl C 1 ~C 6 Alkyl, C 3 ~C 8 Cycloalkyl, C 3 ~C 8 Cycloalkylcarbonyl, C 3 ~C 8 Cycloalkoxy, C 1 ~C 6 an alkylsulfonyl group, optionally having one or two C 1 ~C 6 Aminosulfonyl group having an alkyl group, C 1 ~C 6 an alkylsulfonylamino group or optionally one or two C 1 ~C 6 an amino having an alkyl group; Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R a , R b , m and n are defined as in claim 1; R 4 does not exist.)

7. The heterocyclic compound represented by formula I according to claim 1, characterized in that the heterocyclic compound represented by formula I is selected from any one of the following compounds: 【Chemistry 26】 【Chemistry 27】 【Chemistry 28】

8. The heterocyclic compound represented by formula I is selected from any one of the following compounds: 【Chemical 29】 Alternatively, the heterocyclic compound of formula I is selected from any one of the following compounds: The retention time is 0.743 min under the following SFC conditions: 【Chemistry 30】 Chromatography column: Chiralpak AD-3 50×4.6 mm I.D., 3 μm, mobile phase: mobile phase A: CO 2 , Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; The retention time is 1.670 min under the following SFC conditions: 【Chemistry 31】 Chromatography column: Chiralpak AD-3 50×4.6 mm I.D., 3 μm, mobile phase: mobile phase A: CO 2 , Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; The retention time is 0.816 min under the following SFC conditions: 【Chemistry 32】 Chromatography column: Chiralpak AS-3 50×4.6 mm I.D., 3 μm; Mobile phase: Mobile phase A: CO 2 Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 40 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; The retention time is 1.477 min under the following SFC conditions: 【Chemical 33】 Chromatography column: Chiralpak AS-3 50×4.6 mm I.D., 3 μm; Mobile phase: Mobile phase A: CO 2 Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 40 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; The retention time is 0.764 min under the following SFC conditions: 【Chemical Formula 34】 Chromatography column: Chiralpak AD-3 50×4.6 mm I.D., 3 μm, mobile phase: mobile phase A: CO 2 Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; and a retention time of 1.702 min under the following SFC conditions: 【Chemistry 35】 Chromatography column: Chiralpak AD-3 50×4.6 mm I.D., 3 μm, mobile phase: mobile phase A: CO 2 Mobile phase B: a solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine; Isocratic elution: CO 2 50 volume percent solution of isopropanol and acetonitrile with 0.05 volume percent diethylamine at 25° C.; flow rate: 3 mL / min; detector: PDA; column temperature: 35° C.; column pressure: 100 Bar; Alternatively, the heterocyclic compound of formula I is selected from any one of the following compounds: IC under the test conditions of Example 1 50 is 12.16 nM; 【Chemical 36】 IC under the test conditions of Example 1 50 is 3.58 nM; 【Chemical 37】 IC under the test conditions of Example 1 50 is 1.52 nM; 【Chemical 38】 IC under the test conditions of Example 1 50 is 7.42 nM; 【Chemical 39】 IC under the test conditions of Example 1 50 is 15.8 nM; 【Chemistry 40】 And, under the test conditions of Example 1, IC 50 is 3.78 nM; 【Chemistry 41】 Alternatively, a total pulmonary fibrosis score of 3.34 under the test conditions of Example 3; 【Chemistry 42】 Alternatively, under the test conditions of Example 5, C max is 4480 ng / mL; 【Chemistry 43】 Alternatively, under the test conditions of Example 5, AUC (0-t) is 33173 h·ng / mL; 【Chemistry 44】 A heterocyclic compound represented by formula I according to claim 7, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof or a prodrug thereof.

9. A pharmaceutical composition comprising a heterocyclic compound represented by formula I according to any one of claims 1 to 8, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of the pharma- ceutically acceptable salt thereof, or a prodrug thereof, and a pharma- ceutically acceptable carrier.

10. Use of a substance, said substance being a heterocyclic compound of formula I according to any one of claims 1 to 8, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, a prodrug thereof or a pharmaceutical composition according to claim 9, The use of a substance, characterized in that the use is for the manufacture of a 15-PGDH inhibitor or for the manufacture of a medicament for preventing and / or treating a 15-PGDH-associated disease.

11. The use according to claim 10, characterized in that the 15-PGDH associated disease is one, two or more of fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft versus host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, engraftment promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neuronal cell death, blood cell reconstitution, tissue damage, cervical diseases or kidney diseases, preferably one or more of fibrosis, inflammatory diseases or tissue damage.

12. the fibrotic disease is one or more of pulmonary fibrosis, hepatic fibrosis, renal fibrosis, myocardial fibrosis, scleroderma, or myelofibrosis, preferably pulmonary fibrosis, such as pulmonary fibrosis, and / or hepatic fibrosis; The pulmonary fibrosis is preferably idiopathic pulmonary fibrosis; and / or said inflammatory disease is one or more of chronic obstructive pulmonary disease, acute lung injury, sepsis, asthma and exacerbations of pulmonary disease, inflammatory bowel disease, peptic ulcer, autoinflammatory disease, vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease, atopic dermatitis, psoriasis, interstitial cystitis, or prostatitis syndrome, preferably inflammatory bowel disease; The inflammatory bowel disease is preferably ulcerative colitis and / or Crohn's disease, The peptic ulcer is preferably an NSAID-induced ulcer; The autoinflammatory disease is preferably Behcet's disease, The prostatitis syndrome is preferably chronic prostatitis and / or chronic pelvic pain syndrome, And / or the cardiovascular disease is one or more of pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke, or peripheral circulatory disorder; and / or the trauma is one or more of diabetic ulcers, burns, pressure sores, acute mucosal injuries including Sjogren's syndrome, mucosal injuries, injuries associated with anti-cancer chemotherapeutic agents, antimetabolites, cellular or humoral immunotherapy or radiation-related injuries; The anti-cancer chemotherapeutic agent is preferably one or more of an alkylating agent, a DNA synthesis inhibitor, or a DNA gyrase inhibitor; and / or the autoimmune disease is multiple sclerosis and / or rheumatoid arthritis, and / or the ear condition is one or more of hearing loss, tinnitus, dizziness or balance disorders; and / or the eye disease is glaucoma and / or dry eye; and / or the neurogenesis and neuronal cell death is one or more of a neuropsychiatric disorder, a neurological disorder, a neurotoxic disorder, a neuropathic pain or a neurodegenerative disorder; and / or the tissue damage is liver damage and / or muscle damage; The muscle damage is preferably muscle atrophy and / or muscular dystrophy; And / or the use according to claim 11, characterized in that the kidney disease is chronic kidney disease and / or renal failure.

13. The use according to claim 10, wherein the prevention and / or treatment of a 15-PGDH associated disease is prevention and / or treatment of liver regeneration.

14. Use of a heterocyclic compound of formula I according to any one of claims 1 to 8, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, a prodrug thereof or a pharmaceutical composition according to claim 9 in the manufacture of a medicament for the prevention or treatment of a disease which is one or more of a fibrotic disease, an inflammatory disease or tissue injury, comprising Preferably, said fibrotic disease, said inflammatory disease and said tissue damage are all as defined in claim 12.

15. Administering to a subject in need thereof a heterocyclic compound of formula I according to any one of claims 1 to 8, a solvate thereof, a pharma- ceutically acceptable salt thereof, a solvate of a pharma- ceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutical composition according to claim 9, wherein the disease is one or more of a 15-PGDH-associated disease, a fibrotic disease, an inflammatory disease, or a tissue injury; Preferably, the 15-PGDH associated disease is as defined in claim 12, A method for inhibiting 15-PGDH or preventing or treating a disease, wherein the fibrotic disease, the inflammatory disease and the tissue damage are all as described in any one of claims 10 to 13.

Citation Information

Patent Citations

  • Benzoamidopiperidine-containing compounds and related compounds

    JP2004501072A

  • 15-PGDH inhibitor

    WO2020145250A1

  • 15-PGDH inhibitors

    WO2020160151A1

  • PGDH inhibitors and methods of making and using

    WO2021151014A1